TECHNICAL FIELD

[0001] The present disclosure relates to the field of medicinal chemistry and more particularly to the development of compounds as inhibitors of one or more BET family of bromodomians. The present disclosure relates to heterocyclic compounds of the Formula (I), its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient.

(I)

[0002] The present disclosure further relates to the synthesis and characterization of aforementioned compounds to exhibit anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by one or more BET family of bromodomains.

BACKGROUND

[0003] Transcriptional regulation is a major event in cell differentiation, proliferation and apoptosis. Transcriptional activation of a set of genes determines cellular function and is tightly regulated by a variety of factors. One of the regulatory mechanisms involved in this process is an alteration in the tertiary structure of DNA, which affects transcription factors to their target DNA regiments. Nucleosomal integrity is regulated by the acetylation status of the core histone, with the result being permissiveness to transcription. The regulations of transcription factor are thought to involve changes in the structure of chromatin. Changing the affinity of histone proteins for coiled DNA in the nucleosome alters the structure of chromatin. Hypoacetylated histones are believed to have greater affinity to the DNA and form a tightly bound DNA-histone complex and render the DNA inaccessible to transcriptional regulation. The acetylating status of the histone is governed by the balanced activities of the histone acetyl transferase (HAT) and histone deacetylase (HDAC). The bromodomain and extraterminal family of proteins called as BET proteins are readers of the acetyl status of histone and changes the chromatin structure and gene expression.

[0004] The BET family of bromodomain containing proteins comprises four proteins, namely BRD2, BRD3, BRD4 and BRDT, which are widely expressed in various tissues, except BRDT which is localized in the testes. Each of the BRD proteins contains tandem bromodomains capable of binding to acetylated lysine residues in histones H3 and H4. It has been reported that BRD2 and BRD3 are associated with histones along actively transcribed genes and involved in facilitating transcriptional elongation (Leroy et al, Mol. Cell. 2008 30(1):51 -60), while BRD4 appears to be involved in the recruitment of the pTEF-[beta] complex to nuclesomes, which results in phosphorylation of RNA polymerase II and increases the transcriptional elongation of neighboring genes. (Hargreaves et al, Cell, 2009 138(1): 129-145).

[0005] BRD4 or BRD3 may fuse with NUT (nuclear protein in testis) forming novel fusion oncogenes, BRD4-NUT or BRD3-NUT, in a highly malignant form of epithelial neoplasia (French et al. Cancer Research, 2003, 63, 304-307 and French et al. Journal of Clinical Oncology, 2004, 22 (20), 4135-4139). Data suggests that BRD- NUT fusion proteins contribute to carcinogenesis (Oncogene, 2008, 27, 2237-2242). A BET protein which includes BRD4 have been shown to be important regulators of gene expression profiles in numerous diseases such as cancer, diabetes, obesity, cardiovascular and renal disorders. Currently several BRD4 inhibitors is in various stages of clinical trial for cancer such as IBET-762, JQ1, OTX-015 and RVX-2135 (P. Filippakopoulos, et.al., Nature Review Drug Discovery, 13, 2014, 337-356, M. Brand, et.al., ACS Chem.Biol, 10, 2015, 22-39).

[0006] A tricyclic aryl compound as squalene synthase inhibitors has been disclosed in WO2008133288 for the treatment of hypercholesterolemia, hypertriglyceridemia and hypo-HDL cholesterolemia and/or arteriosclerosis.

[0007] Masanori Ichikawa et.al published a paper (ACS Med.Chem.Lett., 2013, 932- 936) describing the squalene synthase inhibitors DF4611 (B) and also Nils Griebenow, et.al. published a paper (Bioorg. Med. Chem. Lett. 21, 2011, 3648-3653) on the synthesis of novel 4H,6H-[2]benzoxepino[4,5-c][l,2]oxazoles (C) as squalene synthase inhibitors.

[0008] Although, there are several chemotherapies and target therapies based drugs for cancer, an effective cure for cancer still remains elusive. Further, development of acquired resistance and disease relapse are major issues that still need to be addressed. Even though several bromodomain inhibitors are known in the clinic as well as in the preclinic, still remains a need for finding potent bromodomain inhibitors having desirable drug like properties.

[0009] Therefore, the present invention provides novel and drug like molecules having good potency as BRD4 inhibitors which can inhibit the binding of acetylated lysine residue of histone for controlling gene expressions in various diseases.

SUMMARY:

[00010] The present disclosure is based on the development of compounds of Formula I (see below) exhibiting advantageous anti-cancer properties. Thus, the present disclosure provides a compound of Formula I

Formula I or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof,

wherein is a single bond or a double bond;X is selected from -O- or -N-;n is

0-6; Riis selected from alkyl or cycloalkyl;R2 and R ₃ are independently selected from hydrogen, halogen, hydroxy, nitro, cyano, azido, nitroso, oxo (=0), thioxo (=S), - S0 ₂ - _, amino, hydrazino, formyl, alkyl, haloalkyl, alkoxy, haloalkoxy; arylalkoxy; cycloalkyl, cycloalkyloxy, aryl, heterocyclyl, heteroaryl, alkylamino, -COOR _a , - C(0)R _b , -C(S)R _a , -C(0)NR _a R _b , -C(S)NR _a R _b , -NR ^a C(0)NR _b R _c , NR _a C(S)NR _b R _c , - N(R _a )SOR _b , -N(R _a )S0 ₂ R _b , -NR _a C(0)OR _b , -NR _a R _b , -NR _a C(0)R _b -, NR _a C(S)R _b -, - SONR _a R _b -, -S0 ₂ NR _a R _b -, -OR _a , -OR _a C(0)OR _b -, -OC(0)NR _a R _b , OC(0)R _a , - OC(0)NR _a R _b -, -R _a NR _b R _c , -R _a OR _b -,-SR _a , -SOR _a or-S0 ₂ R _a , wherein R _a , R _b and R _c are independently selected from hydrogenalkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heteroarylorhetroarylalkyl; R ₄ is selected from hydrogen, alkyl, cycloalkyl, cyloalkenyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl or haloalkyl;Z is selected from hydrogen, -CH ₂ OR ₅ ,- COOR _5, -CONR ₅ R ₆ , -NHCOOR ₅ , -NHCOR ₅ or -NHS0 ₂ R _5; and R ₅ and R ₆ are independently selected from hydrogen, hydroxyl, aryl, heteroaryl, cycloalkyl or alkyl.

[00011] The present disclosure relates to a composition comprising a compound of Formula (I) or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof together with a carrier.

[00012] The present disclosure relates to a pharmaceutical composition comprising a compound of Formula I or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, together with a pharmaceutically acceptable carrier, optionally in combination with one or more other pharmaceutical compositions. [00013] The present disclosure further relates to a method of preventing or treating proliferative diseases by administering a therapeutic effective amount of novel compound of the Formula (I) or a pharmaceutically acceptable salt and/or prodrug.

[00014] The present disclosure relates to a process of preparation of compound of Formula (I) or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof.

[00015] These and other features, aspects, and advantages of the present subject matter will become better understood with reference to the following description. This summary is provided to introduce a selection of concepts in a simplified form. This summary is not intended to identify key features or essential features of the disclosure, nor is it intended to be used to limit the scope of the subject matter.

DETAILED DESCRIPTION

[00016] Those skilled in the art will be aware that the present disclosure is subject to variations and modifications other than those specifically described. It is to be understood that the present disclosure includes all such variations and modifications.

The disclosure also includes all such steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any or more of such steps or features.

Definitions

[00017] For convenience, before further description of the present disclosure, certain terms employed in the specification, and examples are collected here. These definitions should be read in the light of the remainder of the disclosure and understood as by a person of skill in the art. The terms used herein have the meanings recognized and known to those of skill in the art, however, for convenience and completeness, particular terms and their meanings are set forth below. [00018] The articles "a", "an" and "the" are used to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article.

[00019] The terms "comprise" and "comprising" are used in the inclusive, open sense, meaning that additional elements may be included. Throughout this specification, unless the context requires otherwise the word "comprise", and variations, such as "comprises" and "comprising", will be understood to imply the inclusion of a stated element or step or group of element or steps but not the exclusion of any other element or step or group of element or steps.

[00020] The term "including" is used to mean "including but not limited to". "Including" and "including but not limited to" are used interchangeably.

[00021] In the structural formulae given herein and throughout the present disclosure, the following terms have been indicated meaning, unless specifically stated otherwise.

[00022] The term "alkyl" refers to straight or branched aliphatic hydrocarbon chain having the 1-8 carbon atoms. This term is exemplified by groups such as n-butyl, iso- butyl, t-butyl, n-hexyl and the like. The groups may be optionally substituted.

[00023] The term "aryl" refers to aromatic radicals having 5 to 18 carbon atomshaving a single ring (e.g. phenyl) or multiple rings (e.g. biphenyl), or multiple condensed (fused) rings (e.g. naphthyl or anthranyl), which may be optionally substituted by one or more substituents. Preferred aryl groups, without limitation, include phenyl, naphthyl, indanyl, biphenyl and the like.

[00024] The term "arylalkyl" refers to an aryl group directly bonded to an alkyl group, which may be optionally substituted by one or more substituents. Preferred arylalkyl groups, without limitation, include -CH ₂ C ₆ H ₅ , -C ₂ H ₄ C ₆ H ₅ and the like.

[00025] The term "heterocyclyl" refers to a heterocyclic ring radical which may be optionally substituted by one or more substituents. The heterocyclyl ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.

[00026] Furthermore the term "heterocyclyl" refers to a stable 2 to 18 membered rings radical, which consists of carbon atoms and from one to five heteroatom' s selected from nitrogen, phosphorus, oxygen and sulfur. For purposes of this invention the heterocyclic ring radical may be monocyclic, bicyclic or tricyclic ring systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states. In addition, the nitrogen atom may be optionally quaternized; and the ring radical may be partially or fully saturated. Preferred heterocyclyl groups, without limitation, include azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofuranyl, carbazolyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pyrazolyl, pyridyl, pteridinyl, purinyl, quinazolinyl, qunioxalinyl, quinolinyl, isoquinolinyl, tetrazolyl, imidazolyl, tetrahydroisoquinolinyl, piperidinyl, piperazinyl, homopiperazinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolinyl, triazolyl, indanyl, isoxazolyl, isoxazolidinyl, thiazolyl, thiazolinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl, quinolyl, isoquinolyl, decahydroisoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzooxazolyl, thienyl, morpholinyl, thiomorpholinyl, thiamorpholinyl sulfoxide, furyl, tetrahydrofuryl, tetrahydropyranyl, chromanyl and isochromanyl.

[00027] The term "heteroaryl" refers to a heteroaromatic carbocyclic group of 2 to 18 carbon atoms having a single ring (e.g. pyridine) or multiple rings (e.g. isoquinoline), or multiple condensed (fused) rings. Preferred heteroaryls include thiophene, pyrazole, thiazole, pyridine and the like. The groups may be optionally substituted.

[00028] The term "heteroarylalkyl" refers to a heteroaryl group directly bonded to an alkyl group, which may be optionally substituted by one or more substituents. Preferred heteroarylalkyl groups, without limitation, include-Ct -pyridinyl, -C ₂ H ₄ - furyl and the like.

[00029] The term "cycloalkyl" refers to non-aromatic mono or polycyclic ring system of about 3 to 12 carbon atoms, which may be optionally substituted by one or more substituent' s. The polycyclic ring denotes hydrocarbon systems containing two or more ring systems with one or more ring carbon atoms in common, i.e., a spiro, fused or bridged structures. Preferred cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctanyl, perhydronaphthyl, adamantyl, noradamantyl and norbornyl groups, bridged cyclic groups or spirobicyclic groups e.g. spiro [4.4] non-2-yl and the like.

[00030] The term "alkoxy" refers to an alkyl group attached via an oxygen linkage to the rest of the molecule, which may be optionally substituted by one or more substituents. Preferred alkoxy groups, without limitation, include-OCH _3i -OC ₂ H ₅ and the like.

[00031] The term "alkylthio" refers to an alkyl group attached via a sulfur linkage to the rest of the molecule, which may be optionally substituted by one or more substituents. Preferred alkylthio groups, without limitation, include-SCH ₃ , -SC ₂ H ₅ and the like.

[00032] The term "alkylamino" refers to an alkyl group as defined above attached via amino linkage to the rest of the molecule, which may be optionally substituted by one or more substituent' s. Preferred alkylamino groups, without limitation include- NHCH ₃ , -N(CH ₃ ) ₂ , and the like.

[00033] The term "alkenyl" refers to an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched chain having about 2 to 10 carbon atoms, which may be optionally substituted by one or more substituent' s. Preferred alkenyl groups, without limitation, includeethenyl, 1- propenyl, 2-propenyl, iso-propenyl, 2-methyl- 1 -propenyl, 1-butenyl, 2-butenyl and the like.

[00034] The term "alkynyl" refers to a straight or branched hydrocarbyl radicals having at least one carbon-carbon triple bond and having in the range of 2-12 carbon atoms, which may be optionally substituted by one or more substituent' s. Preferred alkynyl groups include, without limitation, ethynyl, propynyl, butynyl and the like. [00035] "Halo" or "Halogen", alone or in combination with any other term means halogens such as chloro (CI), fluoro (F), bromo (Br) and iodo (I).

[00036] Furthermore, the compound of formula (I) can be its derivatives, analogs, tautomeric forms, stereoisomer' s, diastereomers, geometrical isomers, polymorphs, solvates, intermediates, metabolites, prodrugs or pharmaceutically acceptable salts and compositions.

[00037] The compounds described herein may contain one or more chiral centers and/or double bonds and therefore, may exist as stereoisomers, such as double -bond isomers (i.e., geometric isomers), regioisomers, enantiomers or diastereomers. Accordingly, the chemical structures depicted herein encompass all possible enantiomers and stereoisomers of the illustrated or identified compounds including the stereoisomerically pure form (e.g., geometrically pure, enantiomerically pure or diastereomerically pure) and enantiomeric and stereoisomeric mixtures. Enantiomeric and stereoisomeric mixtures can be resolved into their component enantiomers or stereoisomers using separation techniques or chiral synthesis techniques well known to the person skilled in the art. The compounds may also exist in several tautomeric forms including the enol form, the keto form and mixtures thereof. Accordingly, the chemical structures depicted herein encompass all possible tautomeric forms of the illustrated or identified compounds. It is also understood that some isomeric form such as diastereomers, enantiomers and geometrical isomers can be separated by physical and/or chemical methods and by those skilled in the art. Pharmaceutically acceptable solvates may be hydrates or comprising of other solvents of crystallization such as alcohols, ether, and the like.

[00038] The term "solvate", as used herein, refers to a crystal form of a substance which contains solvent.

[00039] The term "hydrate" refers to a solvate wherein the solvent is water.

[00040] The phrase "pharmaceutical acceptable" refers to compounds or compositions that are physiologically tolerable and do not typically produce allergic or similar untoward reaction, including but not limited to gastric upset or dizziness when administered to mammal.

[00041] Pharmaceutically acceptable salts forming part of this invention include salts derived from inorganic bases such as like Li, Na, K, Ca, Mg, Fe, Cu, Zn and Mn; salts of organic bases such as N, N'-diacetylethylenediamine, glucamine, triethylamine, choline, dicyclohexylamine, benzylamine, trialkylamine, thiamine, guanidine, diethanolamine, a-phenylethylamine, piperidine, morpholine, pyridine, hydroxyethylpyrrolidine, hydroxyethylpiperidine, ammonium, substituted ammonium salts, aluminum salts and the like. Salts also include amino acid salts such as glycine, alanine, cystine, cysteine, lysine, arginine, phenylalanine, guanidine etc. Salts may include acid addition salts where appropriate which are sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, tosylates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, ketoglutarates and the like.

[00042] As used herein, the term "substituted" is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Illustrative substituents, for example, include those described herein above. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this disclosure, the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms.

[00043] The term "effective amount" means an amount of a compound or composition which is sufficient enough to significantly and positively modify the symptoms and/or conditions to be treated (e.g., provide a positive clinical response). The effective amount of an active ingredient for use in a pharmaceutical composition will vary with the particular condition being treated, the severity of the condition, the duration of the treatment, the nature of concurrent therapy, the particular active ingredient(s) being employed, the particular pharmaceutically-acceptable excipient(s)/carrier(s) utilized, the route of administration, and like factors within the knowledge and expertise of the attending physician

[00044] The compounds described herein can also be prepared in any solid or liquid physical form, for example the compound can be in a crystalline form, in amorphous form and have any particle size. Furthermore, the compound particles may be micronized or nanoized, or may be agglomerated, particulate granules, powders, oils, oily suspensions or any other form of solid or liquid physical forms.

[00045] The compounds described herein may also exhibit polymorphism. This invention further includes different polymorphs of the compounds of the present invention.

[00046] The term "polymorphs" refers to crystal forms of the same molecule, and different polymorphs may have different physical properties such as, for example, melting temperatures, heats of fusion, solubilities, dissolution rates and/or vibrational spectra as a result of the arrangement or conformation of the molecules in the crystal lattice.

[00047] The term "prodrugs" refers to the precursor of the compound of formula (I), which on administration undergoes chemical conversion by metabolic processes before becoming active pharmacological substances. In general, such prodrugs will be functional derivatives of a compound of the invention, which are readily convertible in vivo into a compound of the invention.

[00048] The present disclosure relates to a compound of Formula I

Formula I

or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, wherein—— is a single bond or a double bond;X is selected from -O- or -N-;n is 0-6;Riis selected from alkyl or cycloalkyl;R2 and R ₃ are independently selected from hydrogen, halogen, hydroxy, nitro, cyano, azido, nitroso, oxo (=0), thioxo (=S), -S0 ₂ - _, amino, hydrazino, formyl, alkyl, haloalkyl, alkoxy, haloalkoxy; arylalkoxy; cycloalkyl, cycloalkyloxy, aryl, heterocyclyl, heteroaryl, alkylamino, -COOR _a , -C(0)R _b , -C(S)R _a , -C(0)NR _a R _b , - C(S)NR _a R _b , -NR ^a C(0)NR _b R _c , NR _a C(S)NR _b R _c , -N(R _a )SOR _b , -N(R _a )S0 ₂ R _b , - NR _a C(0)OR _b , -NR _a R _b , -NR _a C(0)R _b -, NR _a C(S)R _b -, -SONR _a R _b -, -S0 ₂ NR _a R _b -, -OR _a , - OR _a C(0)OR _b -, -OC(0)NR _a R _b , OC(0)R _a , -OC(0)NR _a R _b -, -R _a NR _b R _c , -R _a OR _b -,-SR _a , - SOR _a or-S0 ₂ R _a , wherein R _a , R _b and R _c are independently selected from hydrogenalkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heteroarylorhetroarylalkyl; R ₄ is selected from hydrogen, alkyl, cycloalkyl, cyloalkenyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl or haloalkyl;Z is selected from hydrogen, -CH ₂ OR ₅ ,-COOR ₅ , -CONR ₅ R ₆ , -NHCOOR5, -NHCOR5 or - NHS0 ₂ R _5; and R5 and R ₆ are independently selected from hydrogen, hydroxyl, aryl, heteroaryl, cycloalkyl or alkyl.

[00049] According to an embodiment, the present disclosure relates to a compound of the Formula (I) or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, wherein— is a single bond or a double bond;X is selected from -O- or -N-;n is 0-l;Riis selected from Ci-Cs alkyl or C3-C ₈ cycloalkyl; R ₂ and R ₃ are independently selected from hydrogen, fluoro, chloro, bromo, iodo, hydroxy, nitro, cyano, azido, nitroso, oxo (=0), thioxo (=S), -S0 ₂ - _, amino, hydrazino, formyl, Ci-Csalkyl, Ci-Cshaloalkyl independently substituted with upto three halogen selected from fluoro, chloro, bromo, or iodo, Ci-Csalkoxy, Ci- Cshaloalkoxy; Cs-C^arylalkoxy; C ₃ -C ₈ cycloalkyl, C ₃ -C ₈ cycloalkyloxy, Cs-C^aryl, C ₂ -C ₁₈ heterocyclyl, C ₂ -C ₁₈ heteroaryl, alkylamino, -COOR _a , -C(0)R _b , -C(S)R _a , - C(0)NR _a R _b , -C(S)NR _a R _b , -NR ^a C(0)NR _b R _c , NR _a C(S)NR _b R _c , -N(R _a )SOR _b , - N(R _a )S0 ₂ R _b , -NR _a C(0)OR _b , -NR _a R _b , -NR _a C(0)R _b -, NR _a C(S)R _b -, -SONR _a R _b -, - S0 ₂ NR _a R _b -, -OR _a , -OR _a C(0)OR _b -, -OC(0)NR _a R _b , OC(0)R _a , -OC(0)NR _a R _b -, - R _a NR _b R _c , -R _a OR _b -,-SR _a , -SOR _a or-S0 ₂ R _a , wherein R _a , R _b and R _c are independently selected from hydrogen, Ci-Cs alkyl, C ₃ -C ₈ cycloalkyl, Cs-C ₁₈ aryl, Cs-C^arylalkyl, C ₂ -Ci ₈ heterocyclyl, C ₂ -Ci ₈ heteroaryl and C ₂ -Ci ₈ hetroarylalkyl;R4 is selected from hydrogen, Ci-Csalkyl, C ₂ -C ₈ alkynyl, C ₃ -C ₈ cycloalkyl, C ₃ -C ₈ cyloalkenyl, C ₃ - Cscycloalkylalkyl, Cs-Cigaryl, Cs-Cigarylalkyl, C ₂ -Ci ₈ heterocyclyl, C ₂ - Ci ₈ heterocyclylalkyl, C ₂ -Ci ₈ heteroaryl, C ₂ -Ci ₈ heteroarylalkyl or Ci- C ₈ haloalkyl,wherein alkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl are independently unsubstituted or substituted with upto three substituents independently selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, acyl, acyloxy, amino, hydroxy, keto, nitro, azido, cyano, amide, sulfonamide and carbamate, wherein the heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl contains upto three heteroatoms selected from O, N or S;Z is selected from hydrogen, -CH ₂ OR ₅ ,-COOR ₅ , -CONR ₅ R ₆ , -NHCOOR ₅ , -NHCOR ₅ or -NHS0 ₂ R ₅ , whereinR ₅ and R ₆ are independently selected from hydrogen, hydroxyl, C ₅ -Ci ₈ aryl, C ₂ -Ci ₈ heteroaryl, C ₃ -C ₈ cycloalkyl or Ci- Csalkyl; wherein R5 and R ₆ are optionally substitutedwithone or more substituents selected from fluorine, chlorine, bromine, iodine,hydroxy, nitro, cyano, azido, nitroso, oxo (=0), thioxo (=S), -S0 ₂ - _i amino, hydrazino, formyl, Ci-Csalkyl, Ci- Cshaloalkylalkoxy, Ci-Cshaloalkoxy; Cs-C^arylalkoxy; C ₃ -C ₈ cycloalkyl, C ₃ - C ₈ cycloalkyloxy, Cs-C ₁₈ aryl, C ₂ -Ci ₈ heterocyclyl, C ₂ -Ci ₈ heteroaryl, alkylamino,

COOR ^a , -C(0)R ^b , -C(S)R ^a , -C(0)NR ^a R ^b , -C(S)NR ^a R ^b , -NR ^a C(0)NR ^b R ^c , NR ^a C(S)NR ^b R ^c , -N(R ^a )SOR ^b , -N(R ^a )S0 ₂ R ^b , -NR ^a C(0)OR ^b , -NR ^a R ^b , -NR ^a C(0)R ^b -, NR ^a C(S)R ^b -, -SONR ^a R ^b -, -S0 ₂ NR ^a R ^b -, -OR ^a , -OR ^a C(0)OR ^b -, -OC(0)NR ^a R ^b , OC(0)R ^a , -OC(0)NR ^a R ^b -, -R ^a NR ^b R ^c , -R ^a OR ^b -,-SR ^a , -SOR ^a or-S0 ₂ R ^a , wherein R ^a , R ^b and R ^c are independently selected fromhydrogen, or optionally substituted groups selected from alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heteroarylorhetroarylalkyl.

[00050] According to another embodiment, the present disclosure relates to the compound of Formula (1) or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, wherein,— is a single bond or a double bond;X is selected from -O- or -N-;n is 0-1 ;Ri is selected from hydrogen, methyl, ethyl, n-propyl, ispopropyl, n-butyl, isobutyl, t-butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentylorcyclohexyl;R ₂ and R ₃ are independently selected from hydrogen, fluorine, chlorine, bromine, iodine; hydroxy, nitro, cyano, azido, nitroso, oxo (=0), thioxo (=S), -S0 ₂ - _i amino, hydrazino, formyl, alkyl, haloalkyl group such as trifluoromethyl, tribromomethyl, trichloromethyl and the like; alkoxy, haloalkoxy such as -OCH ₂ Cl and the like; arylalkoxy such as benzyloxy, phenylethoxy and the like; cycloalkyl, cycloalkyloxy, aryl, heterocyclyl, heteroaryl, alkylamino, -COOR _a , -C(0)R _b , -C(S)R _a , -C(0)NR _a R _b , -C(S)NR _a R _b , - NR ^a C(0)NR _b R _c , NR _a C(S)NR _b R _c , -N(R _a )SOR _b , -N(R _a )S0 ₂ R _b , -NR _a C(0)OR _b , -NR _a R _b , -NR _a C(0)R _b -, NR _a C(S)R _b -, -SONR _a R _b -, -S0 ₂ NR _a R _b -, -OR _a , -OR _a C(0)OR _b -, - OC(0)NR _a R _b , OC(0)R _a , -OC(0)NR _a R _b -, -R _a NR _b R _c , -R _a OR _b -,-SR _a , -SOR _a or - S0 ₂ R _a , wherein R _a , R _b and R _c are independently selected from hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heteroaryl and hetroarylalkyl. R ₄ is selected from hydrogen and a substituted or unsubstituted aryl comprising of phenyl, naphthyl, biphenyl and indanyl; heteroaryl comprising of pyridinyl, pyridazinyl, pyrimidyl, triazinyl, pyrrolyl, indolyl, pyrazolyl, imidazolyl, pyrazinyl, pyrimidinyl, tetrazolyl, furyl, thienyl, thiazolyl, isoxazolyl, oxazolyl and quinolinyl; cycloalkyl group comprising of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cyclooctyl; an alkyl group comprising of methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl, heptyl and octyl; haloalkyl group comprising of trichloromethyl, trifluoromethyl, difluoromethyl, trifluoroethyl, trichloroethyl, monofluoromethyl or monochloromethyl;Z is selected from hydrogen, -CH ₂ OR ₅ , -COOR ₅ , -CONR ₅ R ₆ , - NHCOOR ₅ , -NHCOR ₅ , or -NHSO ₂ R ₅ , wherein R ₅ and R ₆ are selected from hydrogen or substituted or unsubstituted aryl comprising phenyl, naphthyl, biphenyl and indanyl: heteroaryl comprising of pyridinyl, pyridazinyl, pyrimidyl, triazinyl, pyrrolyl, indolyl, pyrazolyl, imidazolyl, pyrazinyl, pyrimidinyl, tetrazolyl, furyl, thienyl, thiazolyl, isoxazolyl, oxazolyl and quinolinyl; cycloalkyl group comprising of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cyclooctyl; an alkyl group comprising of methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl, heptyl and octyl;Rs and R ₆ are optionally substituted with one or more selected from but not limited to halogens such as fluorine, chlorine, bromine, iodine; hydroxy, nitro, cyano, azido, nitroso, oxo (=0), thioxo (=S), -SO ₂ - _, amino, hydrazino, formyl, alkyl, haloalkyl group such as trifluoromethyl, tribromomethyl, trichloromethyl and the like; alkoxy, haloalkoxy such as -OCH ₂ CI and the like; arylalkoxy such as benzyloxy, phenylethoxy and the like; cycloalkyl, cycloalkyloxy, aryl, heterocyclyl, heteroaryl, alkylamino, -COOR ^a , -C(0)R ^b , -C(S)R ^a , -C(0)NR ^a R ^b , -C(S)NR ^a R ^b , - NR ^a C(0)NR ^b R ^c , NR ^a C(S)NR ^b R ^c , -N(R ^a )SOR ^b , -N(R ^a )S0 ₂ R ^b , -NR ^a C(0)OR ^b , -NR ^a R ^b , -NR ^a C(0)R ^b -, NR ^a C(S)R ^b -, -SONR ^a R ^b -, -S0 ₂ NR ^a R ^b -, -OR ^a , -OR ^a C(0)OR ^b -, - OC(0)NR ^a R ^b , OC(0)R ^a , -OC(0)NR ^a R ^b -, -R ^a NR ^b R ^c , -R ^a OR ^b -,-SR ^a , -SOR ^a or-S0 ₂ R ^a , wherein R ^a , R ^b and R ^c are independently selected from hydrogen, or optionally substituted groups selected from alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heteroarylorhetroarylalkyl.

[00051] According to an embodiment, the present disclosure relates to the compound of Formula (1) or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, wherein,— is a single bond;X is -O- ;n is 0-l;Riis selected from Ci-Cs alkyl or C3-C ₈ cycloalkyl; R ₂ is hydrogen;R ₃ is selected from halogen, Ci-Cs alkyl, Ci-Cshaloalkyl substituted upto 3 halogen selected from fluoro, chloro, bromo, oriodo, Ci-Csalkoxy, Ci-Cshaloalkoxy; C ₅ - C^arylalkoxy; C ₃ -C ₈ cycloalkyl, C ₃ -C ₈ cycloalkyloxy, C ₅ -C ₁₈ aryl, C ₂ -Ci ₈ heterocyclyl or C ₂ -Ci ₈ heteroaryl;R4 is selected from hydrogen, Ci-Cs alkyl, C ₃ -C ₈ cycloalkyl, C ₃ - Cscyloalkenyl, C ₃ -C ₈ cycloalkylalkyl, C ₅ -C ₁₈ aryl, Cs-C^arylalkyl, C ₂ - Ci ₈ heterocyclyl, C ₂ -Ci ₈ heterocyclylalkyl, C ₂ -Ci ₈ heteroaryl, C ₂ -Ci ₈ heteroarylalkyl or Ci-C ₈ haloalkyl,wherein alkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl are independently unsubstituted or substituted with upto three substituents independently selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, acyl, acyloxy, amino, hydroxy, keto, nitro, azido, cyano, amide, sulfonamide and carbamate ;wherein the heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl contains upto three heteroatoms selected from O, N or S;Z is selected from the group consisting of hydrogen, -CH ₂ OR ₅ ,-COOR ₅ , -CONR ₅ R ₆ , -NHCOOR5, -NHCOR5 or -NHS0 ₂ R _5; whereinRs and R ₆ are independently selected from hydrogen, hydroxyl, C5-C ₁₈ aryl, C ₂ -Ci ₈ heteroaryl, C ₃ -C ₈ cycloalkyl or Ci-Cs alkyl; whereinRs and R ₆ are optionally substituted with one or more substituents selected fluorine, chlorine, bromine, iodine; hydroxy, nitro, cyano, azido, nitroso, oxo (=0), thioxo (=S), -S0 ₂ - _, amino, hydrazino, formyl, C ₁ -C ₈ alkyl, Ci-Cshaloalkylalkoxy, Ci-Cshaloalkoxy; Cs-C^arylalkoxy; C ₃ - C ₈ cycloalkyl, C ₃ -C ₈ cycloalkyloxy, C ₆ -Ci ₈ aryl, C ₂ -C ^heterocyclyl or C ₂ - Ci ₈ heteroaryl.

[00052] According to an embodiment, the presentdisclosure relates to the compound of Formula (1) or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, wherein,— is a single bond or a double bond;X is selected from -O- or -N-;n is 0-1 ;Ri is selected from Ci-C ₂ alkyl;R ₂ and R ₃ are independently selected from hydrogen, halogen, Ci-Cs haloalkyl, C ₁ -C ₈ alkoxy, and Ci-Cs haloalkoxy;R4 is selected from hydrogen, Ci-Csalkyl, C ₂ - Cgalkynyl, C ₃ -C ₈ cycloalkyl, C ₃ -C ₈ cycloalkylalkyl, Cs-C^aryl, C ₂ -C ^heteroaryl, or Ci-C ₈ haloalkyl,wherein alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl and heteroarylalkyl are independently unsubstituted or substituted with upto three substituents independently selected from halogen, alkyl, and cyano,wherein the heteroaryl contains upto three heteroatoms selected from O or N;Z is selected from hydrogen, -CH ₂ OR ₅ , -COOR5, -CONR ₅ R ₆ , -NHCOOR5, - or NHCOR5, wherein R ₅ and R ₆ are independently selected from hydrogen, Cs-C^aryl, or Ci-Csalkyl; wherein R5 and R ₆ are optionally substituted with one or more substituents selected from fluorine, chlorine, bromine, iodine, hydroxy, and cyano.

[00053] According to an embodiment, the present disclosure relates to the compound of Formula (1) or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, wherein, is a single bond or a double bond; X is selected from -O- or -N-; n is 0-1; Ri is selected from methyl and isopropyl;R ₂ is hydrogen;R ₃ is selected from, halogen, Ci-C ₂ haloalkyl, Ci-C ₂ alkoxy, and Ci-C ₂ haloalkoxy; wherein haloalkyl and haloalkoxy are substituted with one or more substituents selected from fluorine and chlorine; R ₄ is selected from hydrogen, Ci-C ₂ alkyl, C ₃ -C ₅ cycloalkyl, C ₃ -Cscycloalkylalkyl, Cs-C ₆ aryl, C ₅ -C ₆ heteroaryl, or Ci-C ₂ haloalkyl,wherein alkyl, cycloalkylalkyl, aryl, heteroaryl and heteroarylalkyl are independently unsubstituted or substituted with upto three substituents independently selected from halogen, alkyl, cyano amide, sulfonamide and carbamate, wherein the heteroaryl contains one heteroatom as N;Z is selected from hydrogen, -CH ₂ OR ₅ , - COOR5, -CONR5R6, -NHCOOR5, - or NHCOR5, wherein R ₅ and R ₆ are independently selected from hydrogen, C ₆ aryl, or Ci-C ₃ alkyl; wherein C ₆ aryl is substituted with hydroxyl.

[00054] According to another embodiment, the present disclosure relates to the compound of Formula (1) or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, wherein,— is a single bond;X is -0-;n is 0-l ;Riis selected from Ci-Cs alkyl or C3-C ₈ cycloalkyl;R ₂ is hydrogen;R ₃ is selected from halogen, Ci-Cs alkyl, Ci-Cshaloalkyl substituted upto 3 halogen selected from fluoro, chloro, bromo, oriodo, Ci-Csalkoxy, Ci-Cshaloalkoxy; C ₅ -Ci ₈ arylalkoxy; C ₃ -C ₈ cycloalkyl, C ₃ -C ₈ cycloalkyloxy, C ₅ -C ₁₈ aryl, C ₂ - Ci ₈ heterocyclyl or C ₂ -Ci ₈ heteroaryl;R4 is selected from hydrogen, Ci-Cs alkyl, C ₃ - C ₈ cycloalkyl, C ₅ -C ₁₈ aryl, C ₅ -Ci ₈ arylalkyl, C ₂ -Ci ₈ heterocyclyl, C ₂ -Ci ₈ heteroaryl, C ₂ - Ci ₈ heteroarylalkyl or Ci-Cshaloalkyl, wherein alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heteroaryl and heteroarylalkyl are independently unsubstituted or substituted with upto three substituents independently selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, acyl, acyloxy, amino, hydroxy, keto, nitro, azido, cyano;wherein the heterocyclyl, heteroaryl and heteroarylalkyl contains upto three heteroatoms selected from O, N or S;Z is selected from the group consisting of hydrogen, -CH ₂ OR ₅ ,-COOR ₅ , -CONR ₅ R ₆ , -NHCOOR5, -NHCOR5 or -NHS0 ₂ R _5; R ₅ and R ₆ are independently selected from hydrogen, hydroxyl, C5-C ₁₈ aryl, C ₂ - Ci ₈ heteroaryl, C ₃ -C ₈ cycloalkyl or Ci-Cs alkyl; wherein R5 and R ₆ are optionally substituted with one or more substituents selected from fluorine, chlorine, bromine, iodine; hydroxy, nitro, cyano, azido, nitroso, oxo (=0), thioxo (=S), -SO ₂ - _, amino, hydrazino, formyl, C ₁ -C ₈ alkyl, Ci-Cshaloalkylalkoxy, Ci-Cshaloalkoxy; C ₅ - C^arylalkoxy; C ₃ -C ₈ cycloalkyl, C ₃ -C ₈ cycloalkyloxy, C ₆ -Ci ₈ aryl, C ₂ -Ci ₈ heterocyclyl or C ₂ -Ci ₈ heteroaryl.

[00055] According to an embodiment, the present disclosure relates to the compound of Formula (1) or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, wherein,— is a double bond;X is -N- ;n is 0-l;Riis selected from Ci-Cs alkyl or C ₃ -C ₈ cycloalkyl; R ₂ is hydrogen;R ₃ is selected from halogen, Ci-Cs alkyl, Ci-Cshaloalkyl substituted uptothreehalogen selected from fluoro, chloro, bromo, or iodo, Ci-Csalkoxy, Ci-Cshaloalkoxy; C5- C^arylalkoxy; C ₃ -C ₈ cycloalkyl, C ₃ -C ₈ cycloalkyloxy, C ₅ -C ₁₈ aryl, C ₂ -Ci ₈ heterocyclyl or C2-Ci ₈ heteroaryl;R4 is selected from hydrogen, Ci-Cs alkyl, C3-C ₈ cycloalkyl, C ₃ - Cgcyloalkenyl, C ₃ -C ₈ cycloalkylalkyl, C ₅ -C ₁₈ aryl, C ₅ -Ci ₈ arylalkyl, C ₂ - Ci ₈ heterocyclyl, C ₂ -Ci ₈ heterocyclylalkyl, C ₂ -Ci ₈ heteroaryl, C ₂ -Ci ₈ heteroarylalkyl or Ci-Cshaloalkyl; wherein alkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl are independently unsubstituted or substituted with upto three substituents independently selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, acyl, acyloxy, amino, hydroxy, keto, nitro, azido, cyano;wherein the heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl contains upto three heteroatoms selected from O, N or S;Z is selected from the group consisting of hydrogen, -CH ₂ OR ₅ ,-COOR _5, -CONR ₅ R ₆ , -NHCOOR ₅ , -NHCOR ₅ or -NHS0 ₂ R _5; R ₅ and R ₆ are independently selected from hydrogen, hydroxyl, C5-C ₁₈ aryl, C ₂ -Ci ₈ heteroaryl, C ₃ -C ₈ cycloalkyl or Ci-Cs alkyl; whereinRs and R ₆ are optionally substituted with, the one or more substituents are selected from but not limited to halogens such as fluorine, chlorine, bromine, iodine; hydroxy, nitro, cyano, azido, nitroso, oxo (=0), thioxo (=S), -S0 ₂ - _i amino, hydrazino, formyl, Ci-Cs alkyl, C1-C8 haloalkylalkoxy, C ₁ -C ₈ haloalkoxy; C ₅ -C ₁₈ arylalkoxy; C ₃ -C ₈ cycloalkyl, C ₃ -C ₈ cycloalkyloxy, C ₆ -Ci ₈ aryl, C ₂ -Ci ₈ heterocyclyl or C ₂ -Ci ₈ heteroaryl.

[00056] According to an embodiment, the present disclosure relates to the compound of Formula (1) or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, wherein,— is a double bond;X is -N-

;n is 0-l;Riis selected from Ci-Cs alkyl or C 2 3

3-C ₈ cycloalkyl; R is hydrogen;R is selected from halogen, Ci-Cs alkyl, C ₁ -C ₈ haloalkyl substituted upto 3 halogen selected from fluoro, chloro, bromo, iodo, C ₁ -C ₈ alkoxy, C ₁ -C ₈ haloalkoxy; C ₅ -C ₁₈ arylalkoxy; C ₃ -C ₈ cycloalkyl, C ₃ -C ₈ cycloalkyloxy, C ₆ -Ci ₈ aryl, C ₂ -Ci ₈ heterocyclyl or C ₅ -C ₁₈ heteroaryl;R ₄ is selected from hydrogen, Ci-Cs alkyl, C ₃ -C ₈ cycloalkyl, C ₅ - Ci ₈ aryl, C5-C ₁₈ arylalkyl, C ₂ -Cis heterocyclyl, C ₂ -Cis heteroaryl, C ₂ -Cis heteroarylalkyl or Ci-Cs haloalkyl; wherein alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heteroaryl and heteroarylalkyl are independently unsubstituted or substituted with upto three substituents independently selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, acyl, acyloxy, amino, hydroxy, keto, nitro, azido, cyano;wherein the heterocyclyl, heteroaryl and heteroarylalkyl contains upto three heteroatoms selected from O, N or S;Z is selected from the group consisting of hydrogen, -CH ₂ OR ₅ ,-COOR ₅ , -CONR ₅ R ₆ , -NHCOOR5, or -NHCOR ₅ wherein _; R ₅ and R ₆ are independently selected from hydrogen, hydroxyl, C ₆ -Ci8 aryl, C ₂ -Ci8 heteroaryl, C ₃ -C ₈ cycloalkyl or Ci-Cs alkyl wherein;R5 and R ₆ are optionally substituted, with one or more substituents selected from fluorine, chlorine, bromine, iodine; hydroxy, nitro, cyano, azido, nitroso, oxo (=0), thioxo (=S), -SO ₂ - amino, hydrazino, formyl, C ₁ -C ₈ alkyl, C ₁ -C ₈ haloalkylalkoxy, C ₁ -C ₈ haloalkoxy; C5-C ₁₈ arylalkoxy; C ₃ -C ₈ cycloalkyl, C ₃ -C ₈ cycloalkyloxy, C5-C ₁₈ aryl, C ₂ -Ci ₈ heterocyclyl or C ₂ -Ci ₈ heteroaryl.

[00057] According to another embodiment, the presentdisclosure relates to the compound of the Formula (la),

or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, wherein X is selected from -O- or -N-;n is 0-l;Rlis selected from C1-C8 alkyl or C3-C8 cycloalkyl; R2 and R3 are independently selected from hydrogen, fluoro, chloro, bromo, iodo, hydroxy, nitro, cyano, azido, nitroso, oxo (=0), thioxo (=S), -S02-, amino, hydrazino, formyl, C1-C8 alkyl, Cl-C8haloalkylindependently substituted with upto 3 halogen selected from fluoro, chloro, bromo, or iodo, Cl-C8alkoxy, Cl-C8haloalkoxy; C5-C18arylalkoxy; C3-C8cycloalkyl, C3-C8cycloalkyloxy, C5-C18 aryl, C2-C18heterocyclyl, C2- C18heteroaryl, alkylamino, -COORa, -C(0)Rb, -C(S)Ra, -C(0)NRaRb, - C(S)NRaRb, -NRaC(0)NRbRc, NRaC(S)NRbRc, -N(Ra)SORb, -N(Ra)S02Rb, - NRaC(0)ORb, -NRaRb, -NRaC(0)Rb-, NRaC(S)Rb-, -SONRaRb-, -S02NRaRb-, - ORa, -ORaC(0)ORb-, -OC(0)NRaRb, OC(0)Ra, -OC(0)NRaRb-, -RaNRbRc, - RaORb-,-SRa, -SORaor-S02Ra, wherein Ra, Rb and Rcare independently selected from hydrogen, C1-C8 alkyl, C3-C8cycloalkyl, C5-C18aryl, C5-C18arylalkyl, C2- C18heterocyclyl, C2-C18heteroaryl and C2-C 18hetroarylalkyl. R4 is selected from hydrogen, C1-C8 alkyl, C3-C8 cycloalkyl, C6-C18aryl or C2-C18heteroaryl,;wherein alkyl, cycloalkyl, aryl, and heteroarylare independently unsubstituted or substituted with upto three substituents independently selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, acyl, acyloxy, amino, hydroxy, keto, nitro, azido, cyano;wherein the heteroaryl contains upto three heteroatoms selected from O, N or S;Z is selected from -CH20R5,-COOR5, -CONR5R6, or -CONHR7;R5 and R6 are independently selected from hydrogen, hydroxyl, C5-C18 aryl, C2-C18heteroaryl, C3-C8cycloalkyl or C1-C8 alkyl; whereinR5 and R6 are optionally substituted, with one or more substituents selected from fluorine, chlorine, bromine, iodine; hydroxy, nitro, cyano, azido, nitroso, oxo (=0), thioxo (=S), -S02-, amino, hydrazino, formyl, C1-C8 alkyl, C1-C8 haloalkylalkoxy, C1-C8 haloalkoxy; C5-C18 arylalkoxy; C3-C8 cycloalkyl, C3-C8 cycloalkyloxy, C5-C18 aryl, C2-C18 heterocyclyl, C2-C18 heteroaryl, alkylamino, -COORa, -C(0)Rb, -C(S)Ra, -C(0)NRaRb, -C(S)NRaRb, - NRaC(0)NRbRc, NRaC(S)NRbRc, -N(Ra)SORb, -N(Ra)S02Rb, -NRaC(0)ORb, - NRaRb, -NRaC(0)Rb-, NRaC(S)Rb-, -SONRaRb-, -S02NRaRb-, -ORa, - ORaC(0)ORb-, -OC(0)NRaRb, OC(0)Ra, -OC(0)NRaRb-, -RaNRbRc, -RaORb-,- SRa, -SORaor-S02Ra, wherein Ra, Rb and Rcare independently selected from hydrogen, or optionally substituted groups selected from alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heteroarylorhetroarylalkyl. R7 represents -OR8, ortho substituted aniline, amino aryl and amino heteroaryl, which may be further substituted, wherein R8 is selected from hydrogen, optionally substituted groups selected from alkyl, aryl, heterocyclyl and -COR9, wherein R9 is selected from alkyl, aryl, heteroaryl, cycloalkylorheterocyclyl.

[00058] According to an embodiment, the present disclosure relates to a compound of Forluma la

(I a)

their analogs, tautomeric forms, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof which can be used for the treatment of proliferative diseases;

wherein,

Rirepresents substituted or unsubstituted alkyl or cycloalkyl ; X represents -O- or - N-; R ₄ represent hydrogen or substituted or unsubstituted aryl, heteroaryl, cycloalkyl and alkyl; Z represents -CH ₂ OR ₅ ,-COOR ₅ or -CONR ₅ R ₆ , -CONHR _7; R ₅ and R ₆ represent hydrogen or substituted or unsubstituted aryl, heteroaryl, cycloalkyl and alkyl; R represents -ORs, ortho substituted aniline, amino aryl and amino heteroaryl, which may be further substituted, wherein Rg represents hydrogen, optionally substituted groups selected from alkyl, aryl, heterocyclyl and -COR ₉ , wherein R ₉ represents optionally substituted groups selected from alkyl, aryl, heteroaryl, cycloalkyl and heterocyclyl ;n represents an integer from 0-6; R ₂ and R3 represent substitution which are independently selected from hydrogen, be one or more are selected from but not limited to halogens such as fluorine, chlorine, bromine, iodine; hydroxy, nitro, cyano, azido, nitroso, oxo (=0), thioxo (=S), -S0 ₂ - _, amino, hydrazino, formyl, alkyl, haloalkyl group such as trifluoromethyl, tribromomethyl, trichloromethyl and the like; alkoxy, haloalkoxy such as -OCH ₂ Cl and the like; arylalkoxy such as benzyloxy, phenylethoxy and the like; cycloalkyl, cycloalkyloxy, aryl, heterocyclyl, heteroaryl, alkylamino, -COOR _a , -C(0)R _b , -C(S)R _a , -C(0)NR ^a R _b , -C(S)NR _a R _b , -NR _a C(0)NR _b R _c , NR _a C(S)NR _b R _c , -N(R _a )SOR _b , -N(R _a )S0 ₂ R _b , - NR _a C(0)OR _b , -NR _a R _b , -NR _a C(0)R _b -, NR _a C(S)R _b -, -SONR _a R _b -, -S0 ₂ NR _a R _b -, -OR _a , - OR _a C(0)OR _b -, -OC(0)NR _a R _b , OC(0)R _a , -OC(0)NR _a R _b -, -R _a NR _b R _c , -R _a OR _b -,-SR _a , - SOR _a and -S0 ₂ R _a , wherein R _a , R _b and R _c in each of the above groups can be hydrogen, optionally substituted groups selected from alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heteroaryl and hetroarylalkyl. The substituents are optionally further substituted by one or more substituents as defined above.

[00059] According to an embodiment, the present disclosure relates to a compound of Formula I or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, wherein,Ri is methyl or iso-propyl.

[00060] According to an embodiment, the present disclosure relates to a compound of Formula I or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, wherein, R ₂ is hydrogen.

[00061] According to an embodiment, the present disclosure relates to a compound of Formula I or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, wherein, R ₃ is selected from Ci- Cgalkoxy, Ci-Cshaloalkyl, halogen or Ci-C8 haloalkoxy.

[00062] According to an embodiment, the present disclosure relates to a compound of Formula I or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, wherein, R ₃ is selected from methoxy, trifluoromethyl, fluorine, or difluoromethoxy.

[00063] According to an embodiment, the present disclosure relates to a compound of Formula I or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, wherein, R ₄ is selected from CI alkyl, Cscycloalkyl, C ₆ cycloalkyl Cscycloalkylalkyl, C ₆ aryl, C ₅ heteroaryl, or Cihaloalkyl,wherein alkyl, cycloalkylalkyl, aryl, heteroaryl and heteroarylalkyl are independently unsubstituted or substituted with upto three substituents independently selected from fluorine, chlorine, methyl and cyano, wherein the heteroaryl contains one heteroatom as N.

[00064] According to an embodiment, the present disclosure relates to a compound of Formula I or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, wherein, X is -N-.

[00065] According to an embodiment, the present disclosure relates to a compound of Formula I or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, wherein, X is -O-..

[00066] According to an embodiment, the present disclosure relates to a compound of Formula I or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, wherein, n is 1.

[00067] According to an embodiment, the present disclosure relates to a compound of Formula I or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, which is selected from a group consisting of:

1) ±Ethyl-2-(-7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-2,3, 5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)acetate

IA) Ethyl 2-((5S,7R)-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-2,3, 5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)acetate

IB) Ethyl 2-((5S,7S)-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-2,3,5,7 - tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)acetate

IC) Ethyl 2-((5R,7S)-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-2,3, 5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)acetate

ID) Ethyl 2-((5R,7R)-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-2,3,5,7 - tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)acetate

2) ±Ethyl-2-(7-cyclohexyl-9-methoxy-2-methyl-3-oxo-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)acetate

3) ±Ethyl-2-(7-(cyclopropylmethyl)-9-methoxy-2-methyl-3-oxo-2, 3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)acetate

4) ±Ethyl-2-(9-methoxy-2-methyl-7-(5-methylpyridin-2-yl)-3-oxo -2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)acetate

5) ±Ethyl-2-(7-(4-chlorophenyl)-9-fluoro-2-methyl-3-oxo-2,3,5, 7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)acetate

6) ±Ethyl-2-(7-(4-chlorophenyl)-2-methyl-3-oxo-9-(trifluoromet hyl)-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)acetate

7) ±7-(4-chlorophenyl)-5-(2-hydroxyethyl)-9-methoxy-2-methyl-5 ,7- dihydrobenzo[5,6]oxepino[4,3-c]pyridin-3(2H)-one

8) ±2-(-7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

8A)±2-((5S,7R)-7-(4-chlorophenyl)-9-methoxy-2-methyl-3-o xo-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

8B)±2-((5S,7S)-7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo- 2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

8C)2-((5S,7R)-7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-2, 3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

8D)2-((5S,7S)-7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-2, 3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

8E)2-((5R,7S)-7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-2, 3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide 8F)2-((5R,7R)-7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-2, 3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

9) ±2-(7-cyclohexyl-9-methoxy-2-methyl-3-oxo-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

9A)±2-((5S,7R)-7-cyclohexyl-9-methoxy-2-methyl-3-oxo-2,3,5, 7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

9B)±2-((5S,7S)-7-cyclohexyl-9-methoxy-2-methyl-3-oxo-2,3 ,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

10) ±2-(7-(cyclopropylmethyl)-9-methoxy-2-methyl-3-oxo-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

10A)±2-((5S,7R)-7-(cyclopropylmethyl)-9-methoxy-2-methyl -3-oxo-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

10B)±2-((5S,7S)-7-(cyclopropylmethyl)-9-methoxy-2-methyl -3-oxo-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

11) ±2-(9-methoxy-2-methyl-7-(5-methylpyridin-2-yl)-3-oxo-2,3,5 ,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

IIA) ±2-((5S,7S)-9-methoxy-2-methyl-7-(5-methylpyridin-2-yl)-3-o xo-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

IIB) ±2-((5S,7R)-9-methoxy-2-methyl-7-(5-methylpyridin-2-yl)-3-o xo-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

12) ±2-(7-(4-chlorophenyl)-9-fluoro-2-methyl-3-oxo-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

12A)±2-((5S,7R)-9-fluoro-2-methyl-3-oxo-7-phenyl-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

12B)±2-((5S,7S)-9-fluoro-2-methyl-3-oxo-7-phenyl-2,3,5,7 - tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

13) ±2-(7-(4-chlorophenyl)-2-methyl-3-oxo-9-(trifluoromethyl)-2 ,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide 13A)±2-((5S,7R)-2-methyl-3-oxo-7-phenyl-9-(trifluoromethyl) -2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

13B)±2-((5S,7S)-2-methyl-3-oxo-7-phenyl-9-(trifluorometh yl)-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

14) ±Ethyl-2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3,5-d ihydro-2H- benzo [c]pyrido [3 ,4-e] azepin-5-yl)acetate

15) ±Ethyl 2-(7-cyclohexyl-9-methoxy-2-methyl-3-oxo-3,5-dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)acetate

16) ±Ethyl-2-(9-methoxy-2-methyl-3-oxo-7-(pyridin-2-yl)-3,5-dih ydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)acetate

17) ±Ethyl-2-(7-(cyclopropylmethyl)-9-methoxy-2-methyl-3-oxo-3, 5-dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)acetate

18) ±Ethyl-2-(9-methoxy-2-methyl-3-oxo-7-(trifluoromethyl)-3,5- dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)acetate

19) ±Ethyl-2-(9-methoxy-2,7-dimethyl-3-oxo-3,5-dihydro-2H-benzo [c]pyrido[3,4- e]azepin-5-yl)acetate

20) ±Ethyl-2-(9-methoxy-2-methyl-7-(5-methylpyridin-2-yl)-3-oxo -3,5-dihydro- 2H-benzo [c]pyrido [3 ,4-e] azepin-5-yl)acetate

21) ±Ethyl-2-(7-(4-chlorophenyl)-2-isopropyl-9-methoxy-3-oxo-3, 5-dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)acetate

22) ±Ethyl-2-(7-(4-chlorophenyl)-9-fluoro-2-methyl-3-oxo-3,5-di hydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)acetate

23) ±Ethyl-2-(7-(2,6-difluorophenyl)-9-methoxy-2-methyl-3-oxo-3 ,5-dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)acetate

24) ±Ethyl-2-(7-(4-chloro-2-methylphenyl)-9-methoxy-2-methyl-3- oxo-3,5- dihydro-2H-benzo[c]pyrido[3,4-e]azepin-5-yl)acetate

25) ±2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3,5-dihydro -2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide 25A)(S)-2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3,5-d ihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide.

25B)(R)-2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3,5-d ihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide.

26) ±2-(7-cyclohexyl-9-methoxy-2-methyl-3-oxo-3,5-dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

26A)(S)-2-(7-cyclohexyl-9-methoxy-2-methyl-3-oxo-3,5-dihydro -2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

26B)(R)-2-(7-cyclohexyl-9-methoxy-2-methyl-3-oxo-3,5-dihydro -2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

27) ±2-(9-methoxy-2-methyl-3-oxo-7-(pyridin-2-yl)-3,5-dihydro-2 H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

27A)(S)-2-(9-methoxy-2-methyl-3-oxo-7-(pyridin-2-yl)-3,5-dih ydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

27B)(R)-2-(9-methoxy-2-methyl-3-oxo-7-(pyridin-2-yl)-3,5-dih ydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

28) ±2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3,5-dihydro -2H- benzo[c]pyrido[3,4-e]azepin-5-yl)acetamide

29) ±2-(7-(4-chlorophenyl)-9-hydroxy-2-methyl-3-oxo-3,5-dihydro -2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

30) ±2-(7-(cyclopropylmethyl)-9-methoxy-2-methyl-3-oxo-3,5-dihy dro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

30A)(S)-2-(7-(cyclopropylmethyl)-9-methoxy-2-methyl-3-oxo -3,5-dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

30B)(R)-2-(7-(cyclopropylmethyl)-9-methoxy-2-methyl-3-oxo-3, 5-dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

31) ±2-(7-(4-chlorophenyl)-9-(difluoromethoxy)-2-methyl-3-oxo-3 ,5-dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide 32) ±2-(9-methoxy-2-methyl-3-oxo-7-(trifluoromethyl)-3,5-dihydr o-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

32A)(S)-2-(9-methoxy-2-methyl-3-oxo-7-(trifluoromethyl)-3 ,5-dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

32B)(R)-2-(9-methoxy-2-methyl-3-oxo-7-(trifluoromethyl)-3,5- dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

33) ±2-(7-(4-cyanophenyl)-9-methoxy-2-methyl-3-oxo-3,5-dihydro- 2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

34) ±2-(9-methoxy-2-methyl-7-(5-methylpyridin-2-yl)-3-oxo-3,5-d ihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

35) ±2-(7-(4-chlorophenyl)-2-methyl-3-oxo-9-(trifluoromethyl)-3 ,5-dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

36) ±2-(7-(4-chlorophenyl)-2-isopropyl-9-methoxy-3-oxo-3,5-dihy dro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

37) ±2-(7-(4-chlorophenyl)-9-fluoro-2-methyl-3-oxo-3,5-dihydro- 2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

38) ±2-(7-(2,6-difluorophenyl)-9-methoxy-2-methyl-3-oxo-3,5-dih ydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

39) ±2-(7-(4-chloro,2-methylphenyl)-9-methoxy-2-methyl-3-oxo-3, 5-dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

40) ±2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3,5-dihydro -2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-(4-hydroxyphenyl)acetami de

40A)(S)-2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3, 5-dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-(4-hydroxyphenyl)acetami de

40B)(R)-2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3, 5-dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-(4-hydroxyphenyl)acetami de

41) ±7-(4-chlorophenyl)-9-methoxy-2,5-dimethyl-2H-benzo[c]pyrid o[3,4- e] azepin-3 (5H)-one 41A)(S)-7-(4-chlorophenyl)-9-methoxy-2,5-dimethyl-2H-benzo[c ]pyrido[3,4- e] azepin-3 (5H)-one

41B)(R)-7-(4-chlorophenyl)-9-methoxy-2,5-dimethyl-2H-benzo[c ]pyrido[3,4- e] azepin-3 (5H)-one

42) ±7-(4-chlorophenyl)-9-methoxy-2-methyl-2H-benzo[c]pyrido[3, 4-e]azepin- 3(5H)-one

43) ±2-(7-(4-chlorophenyl)-2-methyl-3-oxo-9-(trifluoromethyl)-3 ,5-dihydro-2H- benzo [c]pyrido [3 ,4-e] azepin-5-yl)acetic acid

44) ±2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3,5-dihydro -2H- benzo [c]pyrido [3 ,4-e] azepin-5-yl)acetic acid

45) ±tert-butyl((7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3, 5-dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)methyl)carbamate

46) ±N-((7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3,5-dihydr o-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)methyl)acetamide

[00068] According to an embodiment, the present disclosure relates to a process of preparation of compound of Formula I or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof.

[00069] According to an embodiment, the present disclosure relates to a pharmaceutical composition including a compound of Formula (I), or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, and at least one pharmaceutically acceptable carrier, diluent, or excipient.

[00070] According to an embodiment, the present disclosure relates to the use of a compound of Formula (I) or (la) and pharmaceutical composition including a compound of Formula (I) or (la), or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, in the manufacture of a medicament for the treatment and/or prevention of diseases and/or disorders in which aberrant, abnormal or deregulated activity of BET family of bromodomain containing proteins; in particular BRD2, BRD3, BRD4 and BRDT proteins.

[00071] According to an embodiment, the present disclosure relates to the use of a compound of Formula (I) or (la) and pharmaceutical composition including a compound of Formula (I) or (Ia)or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, in the manufacture of a medicament for the production of an anti-cancer effect in a warmblooded animal such as man.

[00072] According to an embodiment, the present disclosure relates to a method for treating a variety of diseases or conditions related to systemic or tissue inflammation, inflammatory responses to infection or hypoxia, cellular activation and proliferation, lipid metabolism, fibrosis and in the prevention and treatment of viral infections.

[00073] According to an embodiment, the present disclosure relates to a method for treating cancer in patients including administration of a therapeutically effective amount of a compound of Formula (I).

[00074] According to an embodiment, the present disclosure relates to a method for treating proliferative conditions or cancer, comprising administering to a subject suffering from proliferative conditions or cancer, a therapeutically effective amount of a compound of Formula (I), in the presence or absence of other clinically relevant cytotoxic agents or non-cytotoxic agents to a mammal in need thereof.

[00075] According to an embodiment, the present disclosure relates to a method for treatinga disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis and the subsequent metastasis including administration of a therapeutically effectiveamount of a compound of Formula (I). [00076] According to an embodiment, the present disclosure relates to a method for treatingcancer in patient including administration of effective amount of compounds of formula (I). The cancer can be either a hematologic malignancy or solid tumor. Hematological malignancy is selected from the group consisting of B-cell lymphoma, T-cell lymphoma and leukemia. In the case of solid tumors, the tumors are selected from the group consisting of breast cancer, lung cancer, ovarian cancer, prostate cancer, head cancer, neck cancer, renal cancer, gastric cancer, colon cancer, pancreatic cancer and brain cancer.

[00077] According to an embodiment, the present disclosure relates to a method for treating and/or preventing a neurodegenerative disease or disorder comprising administering, to a patient in need of treatment, a therapeutically effectively amount of a composition comprising a compound of Formula I and a pharmaceutically acceptable carrier.

[00078] In one aspect of this embodiment, the invention provides a compound of Formula I for use in treating and/or preventing a neurodegenerative disorder or condition. In a related aspect, the invention provides for the use of a compound of Formula I for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder or condition.

[00079] According to an embodiment, the present disclosure relates to the compounds of Formula (I) useful for treating proliferative diseases. A proliferative disease includes, for example, a tumor disease and/or metastates.

[00080] According to an embodiment, the compounds of the present disclosure are useful for treating a proliferative disease that is refractory to the treatment with other chemotherapeutics; or a tumor that is refractory to treatment with other therapeutics due to multidrug resistance.

[00081] According to an embodiment, thepresent disclosure relates to a method of treatment of cancer, said method comprising administering a combination of the compound or the pharmaceutical composition with other clinically relevant immune modulators agents to a mammal in need of thereof. [00082] According to an embodiment, the compounds of the present invention are able to slow tumor growth, stop tumor growth or bring about the regression of tumors and to prevent the formation of tumor metastasis (including micrometastatis) and the growth of metastates (including micrometastatis). In addition they can be used in epidermal hyper proliferation.

[00083] The compound of formula I of the present invention can be used as a prophylactic or therapeutic agent for cancer. Examples of the cancer not restricted include breast cancer, prostate cancer, pancreatic cancer, gastric cancer, lung cancer, colon cancer, rectal cancer, esophagus cancer, duodenal cancer, tongue cancer, pharyngeal cancer, brain tumor, neurinoma, non-small cell lung cancer, small cell lung cancer, liver cancer, kidney cancer, bile duct cancer, uterine body cancer, cervical cancer, ovarian cancer, urinary bladder, skin cancer, hemangioma, malignant lymphoma, malignant melanoma, thyroid cancer, bone tumor, vascular fibroma, retinoblastoma, penile cancer, pediatric solid cancer, lymphoma, myeloma and leukemia (including, for example acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic neutrophilic leukemia, chronic eosinophilic leukemia, chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL) or hariy cell leukemia).

[00084] The compound of formula I of the present invention can be used as a prophylactic or therapeutic agent for various chronic autoimmune and inflammatory conditions such as rheumatoid arthritis, osteoarthritis, acute gout, psoriasis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease (Crohn's disease and Ulcerative colitis), asthma, chronic obstructive airways disease, pneumonitis, myocarditis, pericarditis, myositis, eczema, dermatitis, alopecia, vitiligo, bullous skin diseases, nephritis, vasculitis, atherosclerosis, Alzheimer's disease, depression, retinitis, uveitis, scleritis, hepatitis, pancreatitis, primary biliary cirrhosis, sclerosing cholangitis, Addison's disease, hypophysitis, thyroiditis, type I diabetes and acute rejection of transplanted organs. [00085] In one embodiment, the invention provides a method of inhibiting bromodomain activity comprising administering, to a patient in need of treatment, an amount of a composition comprising a compound of Formula I and a pharmaceutically acceptable carrier sufficient to inhibit bromodomain activity.

[00086] In one aspect of this embodiment, the invention provides a compound of Formula I for use in inhibiting bromodomain. In a related aspect, the invention provides for the use of a compound of Formula I for the manufacture of a medicament for inhibiting bromodomain.

[00087] In one embodiment, the invention provides a method of treating and/or preventing a neurodegenerative disease or disorder comprising administering, to a patient in need of treatment, a therapeutically effectively amount of a composition comprising a compound of Formula I and a pharmaceutically acceptable carrier. In one aspect of this embodiment, the invention provides a compound of Formula I for use in treating and/or preventing a neurodegenerative disorder or condition. In a related aspect, the invention provides for the use of a compound of Formula I for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder or condition.

[00088] In another aspect, the compound may be administered in combination therapy by combining the compound of formula (I) with one or more separate agents, not limited to targets such as DNA methyltransferase, heat shock proteins (e.g. HSP90) kinases and other matrix metalloproteinases.

[00089] "Combination therapy" includes the administration of the subject compounds in further combination with other biologically active ingredients (such as vinblastine, afatinib, nilotinib, vemarafinib, aflibercept, axitinib, dasatinib, sorafenib, bosutinib, crizotinib, but are not limited to, different antineoplastic agent) and non- drug therapies (such as, but are not limited to, surgery or radiation treatment). The compounds described herein can be used in combination with other pharmaceutically active compounds, preferably, which will enhance the effect of the compounds of the invention. The compounds can be administered simultaneously or sequentially to the other drug therapy.

[00090] In another aspect, the subject compounds may be combined with the antineoplastic agents (e.g. small molecules, monoclonal antibodies, antisense RNA and fusion proteins) that inhibit one or more biological targets. Such combination may enhance therapeutic efficacy over the efficacy achieved by any of the agents alone and may prevent or delay the appearance of resistant variants.

[00091] In another aspect, the subject compounds may be combined with immunoncology drugs not restricting to PDL-1 inhibitor, IDO, TDO, CTLA4 or any other drugs which is involved in the immune modulation.

[00092] A term once described, the same meaning applies for it, throughout the patent.

SCHEME:

[00093] According to an embodiment, the present disclosure relates to a process as shown in the following scheme- 1, for the preparation of compounds of the Formula (I), wherein all the groups are as defined earlier.

Scheme 1 [00094] The said process for the preparation of the compounds of formula (I) comprises of the following:

The compound 1 was converted to compound 2 under standard conditions either using malonic acid or witting reagent. Compound 2 was treated with intermediate 3 in the presence of Pd catalyst C-C bond formation under standard conditions to obtained 4. Compound 4 under standard carbonyl reductions using sodium borohydride or sodium cyanoborohydride or like to give the corresponding alcohol 5. Intramolecular cyclization of 5 using bases such as inorganic or organic bases gives 6. Further exploration of 6 gives compound of formula 1. Treating compound 4 with ammonium formate or ammonium acetate or the like in polar protic solvent such as methanol, ethanol or the like gives 7. Further exploration of 7 gives compound of formulal. Compound 1 can be converted to compound 8 by treating corresponding sulfoximine. Compound 8 when treated with appropriately substituted Grignard reagent in the presence of suitable solvents such as tetrahydrofuran or dioxane or diethylether gave compound 9. Compound 9 on treatment with acids such as HC1, H ₂ SO ₄ and the like gave compound of formula 1. Where in R ¹ , R ² , R ³ , R ⁴ and Z are described above. The examples given below are provided by the way of illustration only and therefore should not be construed to limit the scope of the invention.

EXAMPLES

[00095] The following examples provide the details about the synthesis, activities, and applications of the compounds of the present disclosure. It should be understood the following is representative only, and that the invention is not limited by the details set forth in these examples.

Example 1:

[00096] ±Ethyl 2-(-7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)acetate

Step A: methyl 5-bromo-2-oxo-l,2-dihvdropyridine-4-carboxylate-II

[00097] To a stirred solution of Conc.H ₂ S0 ₄ (50 mL, 0.668 mol) in water (500mL) was added methyl 2-amino-5-bromoisonicotinate (I, 50 g, 0.226 mol). The resulting clear brown solution was cooled to 0°C. To the mixture was added NaN0 ₂ (50 g, 0.668 mmol) in water (150 mL) drop wise using addition funnel at 0°C. Vigorous effervescence with evolution of N ₂ gas was observed. The reaction mixture was warmed to room temperature. The reaction mixture was stirred for additional 30 min at room temperature. The solid was filtered, washed with water (3 x 150 mL) followed by n-hexane (2 x 100 mL) to yield as a yellow solid. (48.0 g, 93% yield). ¹ H NMR (DMSO-d ₆ , 400MHz,), δ (ppm): 7.62 (s, 1H), 6.90 (s, 1H), 5.0 (br, 1H), 3.98 (s, 3H). MS (ESI): mass calcd. for C ₇ H ₇ BrN ₂ 0 ₂ , 232.01; m/z found, 234[M+2H] ⁺ . Step B: methyl 5-bromo-l-methyl-2-oxo-l,2-dihvdropyridine-4-carboxylate-III

[00098] To a stirred solution of methyl 5-bromo-2-oxo-l,2-dihydropyridine-4- carboxylate (II, 25.0 g, 0.107 mol) in acetonitrile (500 mL) was added cesium carbonate (42g, 0.129 mol) at 5-10°C. To this mixture was added methyl iodide (7.4 mL, 0.118 mol). The reaction mixture was warmed to room temperature and stirred for 4 h. The reaction mixture was filtered and concentrated to get the product as a brown solid. (25 g, 95% yield), 1H NMR (DMSO-d ₆ , 400MHz,): δ (ppm): 8.18 (s, 1H), 6.70(s, 1H), 3.83(s, 3H), 3.42 (s, 3H). MS (ESI): mass calcd. for C ₈ H ₈ BrN0 ₃ , 246.01; m/z found, 248[M+2H] ⁺ .

Step C: 5-bromo-4-(hvdroxymethyl)-l-methylpyridin-2(lH)-one-IV

[00099] To the 5-bromo-4-(hydroxymethyl)-l-methylpyridin-2(lH)-one (III, 24.0 g, 0.096mol) was added THF (250 mL), DME (250 mL) and NaBH ₄ (10 g, 0.213 mol)at room temperature. The reaction mixture was heated to 75-80°C. To the reaction mixture was added slowly MeOH (250mL) using additional funnel. The reaction mixture was stirred at 70-75°C for lh. The reaction mixture was concentrated under reduced pressure. The concentrate was triturated with 50 mL of water and filtered to yield as a pale yellowish solid. (15.0g, 71% yield), 1H NMR (DMSO- d ₆ , 400MHz,): 5(ppm): 7.98 (s, 1H), 6.44 (s, 1H), 5.56 (br, 1H), 4.29 (s, 2H), 3.38 (s, 3H). MS (ESI): mass calcd. for C ₇ H ₈ BrN0 ₂ , 218.05; m/z found, 220 [M+2H] ⁺ . Step D: 5-bromo-l-methyl-2-oxo-l,2-dihvdropyridine-4-carbaldehyde-V

[000100]To the 5-bromo-4-(hydroxymethyl)-l-methylpyridin-2(lH)-one.(IV, 20.0 g, 0.091 mol) was added acetonitrile (2 L) and stirred at room temperature for 30 mins to get a slightly turbid mixture. To this mixture, Dess-martin-periodinane reagent (60 g, 0.137mol) was added at room temperature. The resulting turbid milky suspension was stirred at room temperature for 3 h. To the reaction mixture was added saturated sodiumbicarbonate aqueous solution (50mL) and stirred for 15min. The reaction mixture was filtered over celite bed. The celite bed was washed with 100 mL of acetonitrile. The acetonitrile organic layer was concentrated 1/3 portion to get a turbid mixture again. The turbid mixture was filtered over celite bed once again and washed with 100 mL of acetonitrile. The acetonitrile organic layer was concentrated to dryness. The residue was dissolved in 5% MeOH in DCM (250 mL) and washed with 50 mL of water. The organic layer was concentrated to get the title compound 5- bromo-l-methyl-2-oxo-l,2-dihydropyridine-4-carbaldehyde as a semi solid (12.3 g, 62% yield), 1H NMR (DMSO-d ₆ , 400MHz,): 5(ppm): 9.94 (s, 1H), 8.23 (s, 1H), 6.81(s, 1H), 3.45 (s, 3H).MS (ESI): mass calcd. for C ₇ H ₆ BrN0 ₂ , 216.03; m/z found, 218[M+2H] ⁺ .

Step E: (E)-ethyl 3-(5-bromo-l-methyl-2-oxo-l,2-dihvdropyridin-4-yl)acrylate-V I

[000101] To a suspension of NaH (2.6 g, 0.064 mol) in dry THF (100 mL) at 0°C was added portion wise triefhylphosphonoacetate (12 mL, 0.06 mol) under nitrogen atmosphere. The reaction mixture was stirred for 30min at 0°C to get a clear solution. To the mixture, 5-bromo-l-methyl-2-oxo-l,2-dihydropyridine-4-carbaldehyde (V, 10 g, 0.046mol) in DMSO(50mL)was added under inert atmosphere. The reaction mixture was warmed to room temperature and stirred for lh. The reaction mixture was quenched with aq. NH ₄ C1 solution (20 mL), extracted with EtOAc (100 mL x 2 times). The combined organic layer was washed with ice cold water lOOmL. The organic layer was dried over anhydrous Na ₂ S04, filtered, and concentrated to get a semi solid. This semi solid was washed with 2 x 50mL of n-pentane to yield as a yellow solid. (9 g, 68% yield), 1H NMR (DMSO- d ₆ ,400MHz,): 5(ppm): 8.15 (s, 1H), 7.49-7.53(d, J=16Hz, 1H), 6.89 (s, 1H), 6.68-6.72 (d, J=16Hz, 1H), 3.41(s, 3H), 4.18- 4.23 (q, J=7.2Hz, 2H), 1.23-1.26 (t, J=6.8Hz, 3H). MS (ESI): mass calcd. for CnHi ₂ BrN0 ₃ , 286.12; m/z found, 288[M+2H] ⁺ .

[000102] Synthesis of Intermediate VII

VI I A VIIB VI IC VIID VII

Step J: 2-bromo-g-(4-chlorophenyl)-5-methoxy-benzenemethanol-VIIC [000103] To a stirred solution of 2-bromo-5-methoxybenzaldehyde (VIIA, 25 g, 116 mmol) in dry tetrahydrofuran (350 mL) under N ₂ atmosphere at 0°C, 4- chlorophenylmagnesium bromide 1.0 M solution in diethyl ether (140 mL, 140 mmol) was added drop wise. Then reaction mixture was left for stirring over 2 h. After the completion of reaction, reaction mixture was quenched by saturated ammonium chloride solution and diluted with ethyl acetate. Reaction mixture was filtered through celite bed. Organic layer was separated and washed with brine, dried over sodium sulphate, concentrated under reduced pressure. The Crude was washed with n-pentane to yield as a off white solid (38 g, 95% yield). MS (ESI): mass calcd for Ci ₄ H ₁₂ BrC10 ₂ , 327.60; m/z found, 326[M-H]\

Step I: (2-bromo-5-methoxyphenyl)(4-chlorophenyl)-Methanone-VIID

[000104] - _{o a} stirred solution of 2-bromo-a-(4-chlorophenyl)-5-methoxy- Benzenemethanol (VIIC, 20 g, 0.06 mol) in dry dichloromethane (350 mL), pyridinium chlorochromate (17 g, 0.078 mol) was added under N ₂ atmosphere. The reaction mixture was stirred for 1.5 h. After the completion of reaction, mixture was filtered through silica gel (100 - 200 mesh) bed. Then dichloromethane layer was washed by saturated sodium bicarbonate solution, followed by brine, dried over sodium sulphate. Organic layer was concentrated and purified using silica gel column chromatography using 2-5% EtOAc/hexane as the eluent to yield as a white solid (13 g, 65% yield). MS (ESI): mass calcd for Ci ₄ Hi ₀ BrClO ₂ , 325.59; m/z found, 326[M+H] ^+'

Step K: (4-chlorophenyl)[5-methoxy-2-(4,4,5,5-tetramethyl-l,3,2-diox aborolan-2- vDphenyllMethanone-VII

[000105] To a stirred solution of (2-bromo-5-methoxyphenyl)(4-chlorophenyl)- Methanone (VIID, 14.8 g, 0.045 mol) in dioxane ( 350 mL), potassium acetate (26.7 g, 0.27 mol) and Bis(pinacolato)diborane (18 g, 0.0726 mol) were added. The mixture was purged with nitrogen gas for 30 min. Then Pd(dppf)Cl ₂ (2.2 g, 0.0027 mol) was added. The reaction mixture was refluxed at 95°C for 2.5 h. After the completion of reaction, reaction mixture was filtered through celite bed. Then dioxane was completely evaporated. Crude was dissolved in ethyl acetate, washed with brine, dried over sodium sulphate, concentrated. The crude was purified by Biotage purifier, eluted in 1% - 3% EA/Hexane to yield as a white solid (10 g, 59% yield). MS (ESI): mass calcd for C ₂₀ H ₂₂ BCIO ₄ , 372.65; m/z found, 373[M+H] ⁺

Step F: (E)-ethyl 3-(5-(2-(4-chlorobenzoyl)-4-methoxyphenyl)-l-methyl-2-oxo-l, 2- dihvdropyridin-4-yl)acrylate-VIII

[000106]To a stirred solution of (E)-ethyl 3-(5-bromo-l-methyl-2-oxo-l,2- dihydropyridin-4-yl)acrylate (VI, 2.0 g, 6.99 mmol) in dimethoxy ethane/water (60: 15 mL), (4-chlorophenyl)(5-methoxy-2-(4,4,5,5-tetramethyl-l,3,2-diox aborolan-2 yl)phenyl)methanone (VII, 3.38 g, 9.08 mmol), sodium carbonate (2.2 mL, 20.97 mmol) was added at room temperature and purged with nitrogen gas for 15 min, followed by Pd(PPh ₃ ) ₄ (0.8 g, 0.699 mmol) was added under nitrogen atmosphere. The mixture was stirred for 28 h at 90 °C. The reaction mixture was cooled to room temperature and concentrated the mixture under reduced pressure. The crude product was dissolved in ethyl acetate. The organic layer was washed with brine, dried over Na ₂ S0 ₄ , concentrated under reduced pressure. The crude was purified by combiflash (Silica gel, 5-80% EtOAc/hexane) to give yellow solid (1.25 g, 40% yield).1H NMR (DMSO-d ₆ ,400MHz,): 5(ppm): 9.13 (s,lH), 8.07 (s, 1H), 7.63-7.61 (d, J = 8.0 Hz, 2H), 7.52-7.50 (d, J = 8.0 Hz, 2H), 4.47 (m, lH), 4.31 (m, lH),4.05 (m, 3H), 3.78(m, 1H), 3.02 (m,lH), 2.74 (m,lH), 2.31 (m,lH), 1.77-1.68 (m,lH), 1.35 (t, J = 4 Hz, 2 H), 1.13 (s, 2H), 0.99 (t, J = 8 Hz, 2 H). MS (ESI): mass calcd. for C25H22CINO5, 451.9; m/z found, 452.1[M+H] ⁺ .

Step G: (E)-efhyl 3-(5-(2-((4-chlorophenyl)(hvdroxy)methyl)-4-methoxyphenyl)-l - methyl-2-oxo- 1 ,2-dihvdropyridin-4-yl)acrylate-IX [000107] To a stirred solution of (E)-ethyl 3-(5-(2-(4-chlorobenzoyl)-4- methoxyphenyl)-l-methyl-2-oxo-l,2-dihydropyridin-4-yl)acryla te (1.25 g, 2.76 mmol) in methanol (30 mL), sodium borohydride (0.153 g, 4.14 mmol) was added at room temperature under nitrogen atmosphere. The reaction mixture was stirred for lh at room temperature. The reaction was monitored by TLC, after completion of the reaction; mixture was quenched with saturated ammonium chloride and concentrated under reduced pressure. The residue was partitioned with ethyl acetate and water. The organic layer was washed with brine, dried over Na ₂ S0 ₄ , concentrated under reduced pressure to yield a yellow solid (1.25 g crude). MS (ESI): mass calcd. for C25H24CINO5, 453.91; m/z found, 454.1[M+H] ⁺ .

Step H: ±ethyl 2-((7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-2, 3,5,7- tetrahydrobenzo[5,61oxepino[4,3-clpyridin-5-yl)acetate-Examp le 1

[000108] To a stirred solution of (E)-ethyl 3-(5-(2-((4- chlorophenyl)(hydroxy)methyl)-4-methoxyphenyl)- 1 -methyl-2-oxo- 1,2- dihydropyridin-4-yl)acrylate (0.15 g, 0.33 mmol) in ethanol (10 mL), potassium carbonate (0.068 g, 0.495 mmol) was added at room temperature under nitrogen atmosphere. The mixture was stirred for 24 h at room temperature. After completion of the reaction, the mixture was quenched with water and concentrated under reduced pressure. The residue was partitioned with ethyl acetate and water. The organic layer was washed with brine, dried over Na ₂ S0 ₄ , concentrated under reduced pressure. The crude was purified by HPLC using Inertsil ODS (250 mm x 4.6 mm x 5μ) column with 0.01% ammonia /water and acetonitrile as mobile phase to yield two diastereomers as white solid (0.05 g, 33.3% yield). MS (ESI): mass calcd. for C25H24CINO5, 453.91; m/z found, 454.2[M+H] ⁺ .

[000109] Preparative Chiral HPLC method for the separation of diastereomers 1

Column: CHIRALPAK IA (250 mm x 4.6 mm x 5μπι)

Wavelength: 254 nm UV

Injection Volume: 25.0 μΐ/min. 20 deg C

Eluent: 80:20:0.1 MTBE: MeOH: DEA

Example 1A:

[000110]Ethyl-2-((5S,7R)-(4-chlorophenyl)-9-methoxy-2-methyl -3-oxo-2,3,5,7- tetrahydrobenzo[5,6]oxepin -c]pyridin-5-yl)acetate

1H NMR (DMSO-d ₆ ,400MHz,): 5(ppm) 7.8 (s,lH), 7.38 (d, J = 8.4 Hz, 1H), 7.25 (d, J = 8.4 Hz, 2H), 7.08 (d, J = 8.4 Hz, 2H), 7.03-7.00 (dd, J = 14.0 Hz, J = 2.0 Hz, 1H), 6.81 (bs, lH), 6.35 (s,lH), 5.95 (s,lH), 4.88 (t, J = 8.4 Hz, 1H), 4.09-4.04 (m, 2H). 3.75 (s, 3H), 3.4 (s, 3H), 2.80-2.78 (m, 2H), 1.16 (t, J = 7.2 Hz, 3H). MS (ESI): mass calcd. for C25H24CINO5, 453.13; m/z found, 454.2[M+H] ⁺ .

Example IB:

[000111]Ethyl-2-((5S,7S)-(4-chlorophenyl)-9-methoxy-2-methyl -3-oxo-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)acetate

1H NMR (DMSO-d ₆ ,400MHz,): 5(ppm) 7.98 (s,lH), 7.45 (d, J = 8.4 Hz, 3H), 7.31 (d, J = 8.0 Hz, 2H), 7.07-7.04 (dd, J = 2.4 Hz, J = 2.4 Hz, 1H), 6.43 (s,lH), 5.96-5.96 (d, J = 1.6 Hz, 1H), 5.48 (s, lH), 4.51 (m, 1Η),4.09-4.07 (m, 2H). 3.63 (s, 3H), 3.53 (s, 3H), 2.95 (d, J = 7.2 Hz, 2H), 1.16 (t, J = 7.2 Hz, 3H). MS (ESI): mass calcd. for C25H24CINO5, 453.13; m/z found, 454.2[M+H] ⁺ .

Example 1C:

[000112]Ethyl-2-((5R,7S)-(4-chlorophenyl)-9-methoxy-2-methyl -3-oxo-2,3,5,7- tetrahydrobenzo[5,6]oxepin -c]pyridin-5-yl)acetate

1H NMR (DMSO-d ₆ ,400MHz,): 5(ppm) 7.8 (s,lH), 7.38 (d, J = 8.4 Hz, 1H), 7.25 (d, J = 8.4 Hz, 2H), 7.08 (d, J = 8.4 Hz, 2H), 7.03-7.00 (dd, J = 14.0 Hz, J = 2.0 Hz, 1H), 6.81 (bs, lH), 6.35 (s,lH), 5.95 (s,lH), 4.88 (t, J = 8.4 Hz, 1H), 4.09-4.04 (m, 2H). 3.75 (s, 3H), 3.4 (s, 3H), 2.80-2.78 (m, 2H), 1.16 (t, J = 7.2 Hz, 3H). MS (ESI): mass calcd. for C25H24CINO5, 453.13; m/z found, 454.2[M+H] ⁺ . Example ID:

[000113]Ethyl-2-((5R,7R)-(4-chlorophenyl)-9-methoxy-2-methyl -3-oxo-2,3,5,7- tetrahydrobenzo[5,6]oxepin -c]pyridin-5-yl)acetate

1H NMR (DMSO-d ₆ ,400MHz,): 5(ppm) 7.98 (s,lH), 7.45 (d, J = 8.4 Hz, 3H), 7.31 (d, J = 8.0 Hz, 2H), 7.07-7.04 (dd, J = 2.4 Hz, J = 2.4 Hz, 1H), 6.43 (s,lH), 5.96-5.96 (d, J = 1.6 Hz, 1H), 5.48 (s, lH), 4.51 (m, 1Η),4.09-4.07 (m, 2H). 3.63 (s, 3H), 3.53 (s, 3H), 2.95 (d, J = 7.2 Hz, 2H), 1.16 (t, J = 7.2 Hz, 3H). MS (ESI): mass calcd. for C25H24CINO5, 453.13; m/z found, 454.2[M+H] ⁺ .

Following compounds were synthesized using the above procedure as exemplified in example 1

Example 2:

[000114] ±Ethyl-2-(7-cyclohexyl-9-methoxy-2-methyl-3-oxo-2,3, 5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)acetate

MS (ESI): mass calcd. for C25H31NO5, 425.1; m/z found, 426.2[M+H] ⁺ . Example 3:

[000115] ±Ethyl-2-(7-(cyclopropylmethyl)-9-methoxy-2-methyl-3-oxo-: tetrahydrobenzo[5,6]oxepino -c]pyridin-5-yl)acetate

MS (ESI): mass calcd. for C23H27NO5, 397.2; m/z found, 398.2 [M+H]

Example 4:

[000116] ±Ethyl-2-(9-methoxy-2-methyl-7-(5-methylpyridin-2-yl)-3-oxo -: tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)acetate

MS (ESI): mass calcd. for C25H26N2O5, 434.2; m/z found, 435.2[M+H]

Example 5:

[000117] ±Ethyl-2-(7-(4-chlorophenyl)-9-fluoro-2-methyl-3-oxo-2,3,5, tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)acetate

(ESI): mass calcd for C ₂₄ H ₂₁ CIFNO ₄ , 441.2; m/z found, 442.2 [M+H] ⁺ .

Example 6:

[000118]±Ethyl-2-(7-(4-chlorophenyl)-2-methyl-3-oxo-9-(trif luoromethyl)-2,3,5,7- tetrahydrobenzo[5,6]oxepin -c]pyridin-5-yl)acetate

(ESI): mass calcd for C ₂₅ H ₂₁ CIF ₃ NO ₄ , 491.3; m/z found, 492.3 [M+H] ⁺ .

Example 7:

[000119]±7(4-chlorophenyl)-5- (2- hydroxyethyl) 9-methoxy,2-methyl, 5,7dihydrobenzo[5,6]oxepino[4,3-c]pyridin-3(2H)-one

To a stirred solution of ethyl 2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo- 2,3,5,7-tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)aceta te (example 1) (0.025g, 0.055 mmol) in dry THF (1 mL), at 0°C Lithium Aluminium Hydride (0.0023, 0.06 mmol, 2M in THF) was added dropwise and stirred at same temperature for lh. After the completion of reaction, reaction mixture was quenched with saturated ammonium chloride solution. Reaction mixture was extracted with DCM dried over sodium sulphate and concentrated. The crude product was purified by Biotage purifier, eluted in 1% - 5% DCM/Methanol to yield 7-(4-chlorophenyl)-5-(2-hydroxyethyl)-9- methoxy-2-methyl-5,7-dihydrobenzo[5,6]oxepino[4,3-c]pyridin- 3(2H)-one as a off- white solid (8 mg, 35% yield). 1H NMR (DMSO-d ₆ , 400MHz,): 5(ppm) 7.78 (s, 1H), 7.37 (d, J = 8.4 Hz, 1H), 7.27 (d, J = 7.6 Hz, 2H), 7.12 (d, J = 7.6 Hz, 2H). 7.00 (d, J = 8.4 Hz, 1H), 6.68 (s, 1H), 6.34 (s, 1H), 5.92 (s, 1H), 4.70 - 4.60 (m, 1H), 4.50 - 4.45 (m, 1H), 3.72 (s, 3H), 3.60 - 3.48 (m, 2H), 3.43 (s, 3H), 1.82 - 1.70 (m, 2H). MS (ESI): mass calcd. for C23H22CINO4, 411.1; m/z found, 412.1 [M+H] ⁺ .-

Example 8:

[000120] ±2-(7-(4- chlorophenyl)9methoxy2methyl3oxo2,3,5,7tetrahydrobenzo[5,6]o xepino[4,3- c]pyridin-5-yl)-N-ethylacetamide

To a stirred solution of ethyl 2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo- 2,3,5,7-tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)aceta te (example 1) (0.5g, 1.1 mmol) in THF (2 mL), trimethyl aluminium (4.4 mL, 8.8 mmol) and 2 M ethyl amine solution (4.4 mL, 8.8 mmol) was added at 0 °C under nitrogen atmosphere. The mixture was stirred for lh at 90 °C. The mixture was quenched with saturated ammonium chloride. The residue was partitioned with ethyl acetate and water. The organic layer was washed with cold water, dried over Na ₂ S0 ₄ , concentrated under reduced pressure. The crude was purified by HPLC using InertsilODS (250 mm x 4.6 mm x 5μ) column with 0.01% ammonia /water and ACN as mobile phase with UV detection 254 nm was utilized. 160 mg of a mixture of diastereomer 8 A and 140 mg of a mixture of diastereomer 8B obtained.

[000121] Preparative Chiral HPLC method for the separation of diastereomers 8A and 8B: Column: CHIRALPAK IA (250 mm x 4.6 mm x 5μπι)

Wavelength: 254 nm UV

Injection Volume: 25.0 μΐ/min. 20 deg C

Eluent: 80:20:0.1 MTBE: MeOH: DEA

Example 8C:

[000122]2-((5S,7R)-7-(4-chlorophenyl)-9-methoxy-2-methyl-3-o xo-2,3,5,7- tetrahydrobenzo[5,6]oxepin -c]pyridin-5-yl)-N-ethylacetamide

1H-NMR (DMSO-Je, 400 MHz) δ (ppm): 7.95 (br. s., 1H), 7.75 (s, 1H), 7.37 (d, = 8.8 Hz, 1H), 7.22 (d, = 8.4 Hz, 2H), 7.04 - 6.99 (m, 3H), 6.92 (s, 1H), 6.30 (s, 1H), 5.97 (s, 1H), 4.86 (t, J = 7.2 Hz, 1H), 3.76 (s, 3H), 3.41 (s, 3H), 3.06- 3.03 (m, 2H), 2.64- 2.62 (m, 2H), 0.98 (t, J = 7.2 Hz, 3H). MS (ESI): mass calcd. for C25H25CIN2O4, 452.2; m/z found, 453.2[M+H] ⁺ .

Example 8D:

[000123]2-((5S,7S)-7-(4-chlorophenyl)-9-methoxy-2-methyl-3-o xo-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

1H-NMR (DMSO-Je, 400 MHz) δ (ppm): 8.02 (br. s., 1H), 7.96 (s, 1H), 7.45 - 7.41 (m, 3H), 7.34 (d, / = 8.4 Hz, 2H), 7.07 - 7.04 (m, 1H), 6.44 (s, 1H), 5.94 (s, 1H), 5.46 (s, 1H), 4.52 (t, J = 6.8 Hz, 1H), 3.62 (s, 3H), 3.53 (s, 3H), 3.10 - 3.00 (m, 2H), 2.70 - 2.68-2.66 (m, 2H), 1.00 (t, J = 7.2 Hz, 3H). MS (ESI): mass calcd. for C25H25CIN2O4, 452.2; m/z found, 453.2[M+H] ⁺ .

Example 8E:

[000124]2-((5R,7S)-7-(4-chlorophenyl)-9-methoxy-2-methyl-3-o xo- tetrahydrobenzo[5,6]oxepin -c]pyridin-5-yl)-N-ethylacetamide

1H-NMR (DMSO-Je, 400 MHz) δ (ppm): 7.95 (br. s., 1H), 7.75 (s, 1H), 7.37 (d, = 8.8 Hz, 1H), 7.22 (d, = 8.4 Hz, 2H), 7.04 - 6.99 (m, 3H), 6.92 (s, 1H), 6.30 (s, 1H), 5.97 (s, 1H), 4.86 (t, J = 7.2 Hz, 1H), 3.76 (s, 3H), 3.41 (s, 3H), 3.06- 3.03 (m, 2H), 2.64- 2.62 (m, 2H), 0.98 (t, J = 7.2 Hz, 3H). MS (ESI): mass calcd. for C25H25CIN2O4, 452.2; m/z found, 453.2[M+H] ⁺ . Example 8F:

[000125]2-((5R,7R)-7-(4-chlorophenyl)-9-methoxy-2-methyl-3-o xo- tetrahydrobenzo[5,6]oxepin -c]pyridin-5-yl)-N-ethylacetamide

1H-NMR (DMSO-Je, 400 MHz) δ (ppm): 8.02 (br. s., 1H), 7.96 (s, 1H), 7.45 - 7.41 (m, 3H), 7.34 (d, = 8.4 Hz, 2H), 7.07 - 7.04 (m, 1H), 6.44 (s, 1H), 5.94 (s, 1H), 5.46 (s, 1H), 4.52 (t, J = 6.8 Hz, 1H), 3.62 (s, 3H), 3.53 (s, 3H), 3.10 - 3.00 (m, 2H), 2.70 - 2.68-2.66 (m, 2H), 1.00 (t, J = 7.2 Hz, 3H). MS (ESI): mass calcd. for C25H25CIN2O4, 452.2; m/z found, 453.2[M+H] ⁺ .

Following compounds were synthesized using the above procedure as exemplified in example 8

Example 9:

[000126] ±2-(7-cyclohexyl-9-methoxy-2-methyl-3-oxo-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

This compound was synthesized and purified as described for synthesizing compound 8 and the diastereoisomers were separated by HPLC to give 9 A and 9B using similar conditions for separating 8A and 8B

Example 9A:

[000127] ±2-((5S,7R)-7-cyclohexyl-9-methoxy-2-methyl-3-oxo-2,3,5,7- tetrahydrobenzo[5,6]oxepin -c]pyridin-5-yl)-N-ethylacetamide

1HNMR: (400 MHz, DMSO-d ₆ ) 7.91 (br.s, IH) 7.83 (s, IH) 7.36 (d, J=8.4Hz, IH) 7.02-7.01 (m, IH) 6.94-6.92 (m, IH), 6.23 (s, IH), 4.66-4.63 (m, IH), 4.60-4.58 (m, IH), 3.78 (m, 3H), 3.48 (s, 3H), 3.07-3.00 (m, 2H), 2.66-2.53 (m, 2H), 1.56-1.47 (m, 4H), 1.37 (m, IH), 1.22 (m, IH), 1.33-0.98 (m, 6H), 0.89-0.85 (m, 2H). (ESI): mass calcd for C25H32N2O4, 424.3; m/z found, 425.0 [M+H] ⁺ .

Example 9B:

[000128]±2-((5S,7S)-7-cyclohexyl-9-methoxy-2-methyl-3-oxo-2 ,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

(ESI): mass calcd for C25H32N2O4, 424.3; m/z found, 425.0 [M+H] ⁺ .

Example 10: [000129]±2-(7-(cyclopropylmethyl)-9-methoxy-2-methyl-3-oxo- 2,3,5,7- tetrahydrobenzo[5,6]oxepin -c]pyridin-5-yl)-N-ethylacetamide

Compound 10 was synthesized and purified as described for synthesizing compound 8 and the diastereoisomers were separated by HPLC to give 10A and 10B using similar conditions for separating 8A and 8B

Example 10A:

[000130]±2-((5S,7R)-7-(cyclopropylmethyl)-9-methoxy-2-methy l-3-oxo-2,3,5,7- tetrahydrobenzo[5,6]oxepin -c]pyridin-5-yl)-N-ethylacetamide

1H-NMR (DMSO-Je, 400 MHz): δ (ppm) 7.90 - 7.85 (m, 2H), 7.34 (d, = 8.4 Hz, 1H), 6.95 (d, / = 8.4 Hz, 1H), 6.85 (s, 1H), 6.26 (s, 1H), 4.81 (t, J = 6.0 Hz, 1H), 4.71 (t, J = 6.8 Hz, 1H), 3.77 (s, 3H), 3.47 (s, 3H), 3.10 - 2.95 (m, 2H), 1.56 - 1.45 (m, 1H), 1.30 - 1.20 (m, 2H), 0.95 (t, J = 6.8 Hz, 3H), 0.55 - 0.45 (m, 1H), 0.3 - 0.15 (m, 2H), (-)0.12 - (-)0.13 (m, 2H). MS (ESI): mass calculated for C23H28N2O4, 396.2; m/z found, 397.2[M+H] ⁺

Example 10B: [000131]±2-((5S,7S)-7-(cyclopropylmethyl)-9-methoxy-2-methy l-3-oxo-2,3,5,7- tetrahydrobenzo[5,6]oxepin -c]pyridin-5-yl)-N-ethylacetamide

1H-NMR (DMSO-Je, 400 MHz): δ (ppm) 7.93 (br. s., 1H), 7.84 (s, 1H), 7.36 (d, = 8.4 Hz, 1H), 7.02 (d, J = 8.4 Hz, 1H), 6.95 (s, 1H), 6.42 (s, 1H), 4.26 (t, J = Hz, 1H), 4.20 (t, J = Hz, 1H), 3.80 (s, 3H), 3.48 (s, 3H), 3.01 - 2.95 (m, 2H), 2.70 - 2.60 (m, 2H), 1.82 - 1.70 (m, 2H), 0.95 (t, J = 7.2 Hz, 3H), 0.75 - 0.60 (m, 1H), 0.33 - 0.31 (m, 2H), 0.05 -0.015 (m, 2H). MS (ESI): mass calculated for C23H28N2O4, 396.2; m/z found, 397.2[M+H] ⁺

Example 11:

[000132]±2-(9-methoxy-2-methyl-7-(5-methylpyridin-2-yl)-3-o xo-2,3,5,7- tetrahydrobenzo[5,6]oxepin -c]pyridin-5-yl)-N-ethylacetamide

Compound 11 was synthesized and purified as described for synthesizing compound 8 and the diastereoisomers were separated by HPLC to give 11A and 11B using similar conditions for separating 8A and 8B. Example 11A:

[000133]±2-((5S,7S)-9-methoxy-2-methyl-7-(5-methylpyridin-2 -yl)-3-oxo-2,3,5,7- tetrahydrobenzo[5,6]oxepin -c]pyridin-5-yl)-N-ethylacetamide

1HNMR: (400 MHz, DMSO-d ₆ ):5(ppm) 8.36 (s, 1H), 8.04 (t, J = 8Hz, 1H), 7.96 (s, 1H), 7.79 (d, J=8Hz, 1H), 7.53 (d, J= 8 Hz, 1H), 7.43 (d, J=8Hz, 1H), 7.05-7.03 (m, 1H), 6.45 (s, 1H), 5.83 (s, 1H), 5.40 (s, 1H), 4.54-4.51 (m, 1H), 3.61 (s, 3H), 3.52 (s, 3H), 3.09-3.00 (m, 2H), 2.70-2.69 (m, 2H), 2.30 (s, 3H), 0.99 (t, J= 8Hz, 3H). (ESI): mass calcd for C25H27N3O4, 433.1; m/z found, 434.2.0 [M+H] ⁺ .

Example 11B:

[000134]±2-((5S,7R)-9-methoxy-2-methyl-7-(5-methylpyridin-2 -yl)-3-oxo-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

(ESI): mass calcd for C25H27N3O4, 433.1 ; m/z found, 434.2.0 [M+H] ⁺ .

Example 12: [000135] ±2-(9-fluoro-2-methyl-3-oxo-7-phenyl-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

Compound 12 was synthesized and purified as described for synthesizing compound 8 and the diastereoisomers were separated by HPLC to give 12A and 12B using similar conditions for separating 8A and 8B

Example 12A:

[000136]±-2-((5S,7R)-7-(4-chlorophenyl)-9-fluoro-2-methyl-3 -oxo-2,3,5,7- tetrahydrobenzo[5,6]oxepin -c]pyridin-5-yl)-N-ethylacetamide

1H NMR (DMSO-d ₆ ,400MHz,): 5(ppm) 8.03 (br.s.,2H), 7.57-7.53 (m, 1H), 7.45 (d, / = 8.0Hz, 2H), 7.36-7.34 (m, 2H), 6.45 (s,lH), 6.16 (d, J = 8.0 Hz, 1H), 5.48 (s, lH), 4.49 - 4.46 (m,lH), 3.52 (s, 3H),3.05-3.01 (m, 3H), 2.69-2.64 (m, 2H),0.98 (t, /= 8.0Hz, 3H); MS(ESI): mass calcd for C24H22CIFN2O3, 440.1; m/z found, 441.2 [M+H] ⁺ .

Example 12B:

[000137] ±2-((5S,7S)-9-fluoro-2-methyl-3-oxo-7-phenyl-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

1H NMR (DMSO-d ₆ ,400MHz,): 5(ppm) 7.93 (s,lH), 7.83 (s, 1H ), 7.50-7.47 (m, 1H), 7.22 (d, J = 8.0Hz, 2H), 7.16 - 7.14 (m , 1H), 7.05 (d, J = 8.0Hz, 2H), 6.31 (s,lH), 5.99 (s,lH), 4.87 - 4.85 (m,lH), 3.41 (s, 3H), 3.05-3.02 (m, 2H), 2.64-2.58 (m, 3H), 0.90(t, J=8.0Hz, 3H); MS(ESI): mass calcd for C24H22CIF 2O3, 440.1; m/z found, 441.2 [M+H] ⁺ .

Example 13:

[000138]2-(7-(4-chlorophenyl)-2-methyl-3-oxo-9-(trifluoro methyl)-2,3,5,7- tetrahydrobenzo[5,6]oxepin -c]pyridin-5-yl)-N-ethylacetamide

Compound 13 was synthesized and purified as described for synthesizing compound 8 and the diastereoisomers were separated by HPLC to give 13A and 13B using similar conditions for separating 8A and 8B Example 13A: [000139]±2-((5S,7R)-7-(4-chlorophenyl)-2-methyl-3-oxo-9-(tr ifluoromethyl)-2,3,5,7- tetrahydrobenzo[5,6]oxepin -c]pyridin-5-yl)-N-ethylacetamide

1H NMR (DMSO-d ₆ ,400MHz,): 5(ppm) 8.15 (s,lH), 8.01 (t, J= 8Hz, 1H), 7.85 (br.s., 1H), 7.75 (d, J = 8.0Hz, 1H), 7.47 (d, J = 8.0Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 6.67 (s,lH), 6.48 (s,lH), 5.57 (s,lH), 4.49(t,J= 8.0Hz, 1H), 3.54 (s, 3H), 3.07 - 3.03(m, 2H), 2.69 (d, J = 4.0Hz, 2H), 0.98 (t, J = 8.0Hz, 3 H). MS (ESI): mass calcd for C25H22CIF3N2O3, 490.1; m/z found, 491.1 [M+H] ⁺ .

Example 13B: [000140]±2-((5S,7S)-7-(4-chlorophenyl)-2-methyl-3-oxo-9-(tr ifluoromethyl)-2,3,5,7- tetrahydrobenzo[5,6]oxepino[4,3-c]pyridin-5-yl)-N-ethylaceta mide

1H NMR (DMSO-d ₆ ,400MHz,): 5(ppm) 7.95 (br.s., 2H), 7.79 (d, J=8Hz, 1H), 7.67 (d, J=8Hz, 2H), 7.24 (d, J=8Hz, 2H), 7.03 (d, J=8Hz, 2H), 6.34 (s, 1H), 6.15(s, 1H), 4.86(t, J = 7.8 Hz, 1H), 3.42(s, 3H), 3.05-3.01(m, 3H), 2.64-2.62(m, 2H), 0.96 (t, J=8Hz, 3H). MS(ESI): mass calcd for C25H22CIF3N2O3, 490.1 ; m/z found, 491.1 [M+H] ⁺ .

Example 14:

[000141] ±-Ethyl-2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3,5- dihydro-2H- benzo c]pyrido[3,4-e]azepin-5-yl)acetate

To a stirred solution of (E)-ethyl 3-(5-(2-(4-chlorobenzoyl)-4-methoxyphenyl)-l- mefhyl-2-oxo- 1 ,2-dihydropyridin-4-yl)acrylate (step F, example 1, compound VIII) (0.0 lg, 0.22 mmol) in ethanol (2 mL), ammonium formate (0.280 mg, 4.4 mmol) was added at room temperature under nitrogen atmosphere. The reaction mixture was stirred at 95°C for 4h. After 4h heating the reaction was monitored by LCMS. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was partitioned with ethyl acetate and water. The organic layer was washed with brine, dried over Na ₂ S0 ₄ and concentrated under reduced pressure to get thick mass. The crude was purified by combi-flash eluting with (0-10%) MeOH: DCM. The pure fractions were concentrated to obtain white solid (15mg, 15%). ^NMR (400 MHz, DMSO-d ₆ ): 5(ppm) 8.02 (s, 1H), 7.65 (d, J=8, 1H), 7.46-7.40 (m, 4H), 7.28-7.25 (m, 1H), 6.75-6.73 (m, 1H), 6.34 (s, 1H), 4.22 - 4.06 (m, 3H), 3.75 (s, 3H), 3.46 (s, 3H), 3.25 -3.14 (m, 2H), 1.17 (t, J = 7.2 Hz, 3H). MS(ESI): mass calcd for C25H23CIN2O4, 450.2; m/z found, 451.2 [M+H] ⁺ .

Following compounds were synthesized using the above procedure as exemplified in example 14 Example 15:

[000142]±Ethyl-2-(7-cyclohexyl-9-methoxy-2-methyl-3-oxo-3,5 -dihydro-2H- benzo[c]pyrido[3,4-e]azepi -5-yl)acetate

MS(ESI): mass calcd for C25H30N2O4, 422.0; m/z found, 423.2 [M+H] ⁺ .

Example 16:

[000143]±Ethyl-2-(9-methoxy-2-methyl-3-oxo-7-(pyridin-2-yl) -3,5-dihyd] benzo[c]pyrido[3,4-e]azepi -5-yl)acetate

MS (ESI): mass calculated for C24H23N3O4, 417.2; m/z found, 418.2.1 [M+H] ⁺ . Example 17:

[000144]±Ethyl-2-(7-(cyclopropylmethyl)-9-methoxy-2-methyl- 3-oxo-3,5-dihydro- 2H-benzo [c]pyrido [3 ,4-e] azepin-5-yl)acetate

MS (ESI): mass calculated for C ₂ oH ₁₉ F ₃ N ₂ 0 ₄ , 394.1; m/z found, 395.1[M+H] ⁺ Example 18:

[000145] ±Ethyl-2-(9-methoxy-2-methyl-3-oxo-7-(trifluoromethyl)-3,5- dihyd] benzo[c]pyrido[3,4-e]azepin-5-yl)acetate

1H-NMR (DMSO-Je, 400 MHz) δ (ppm): 8.06 (s, IH), 7.68 (d, = 8.8 Hz, IH), 7.37- 7.32 (m, IH), 7.11 (s, IH), 6.40 (s, IH), 4.30-4.25 (m, IH), 4.12 - 3.90 (m, 2H), 3.81 (s, 3H), 3.46 (s, 3H), 3.30-3.12 (m, 2H), 1.14 (t, = 6.8 Hz, 3H). MS (ESI): mass calculated for C2oHi ₉ F ₃ N ₂ 0 ₄ , 408.1 ; m/z found, 409.1 [M+H] ⁺

Example 19:

[000146] ±Ethyl-2-(9-methoxy-2,7-dimethyl-3-oxo-3,5-dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)acetate

1H-NMR (DMSO-de, 400 MHz) δ (ppm): 7.90 (s, IH), 7.5 l(d, J = 8.8 Hz, IH), 7.23- 7.22 (m, IH), 7.16 - 7.13 (m, IH), 6.24 (s, IH), 4.03-3.99 (m, 3H), 3.83 (s, 3H), 3.44 (s, 3H), 3.05-3.01 (m, 2H), 2.24(s, 3H), 1.12 (t, J = 7.6 Hz, 3H). MS (ESI): mass calculated for C20H22N2O4, 354.20; m/z found, 355.1 [M+H] ⁺ .

Example 20:

[000147] ±Ethyl-2-(9-methoxy-2-methyl-7-(5-methylpyridin-2-yl)-3-oxo -3,5-dihydro- 2H-benzo [c]pyrido [3 ,4-e] azepin-5-yl)acetate

1HNMR: (400 MHz, DMSO-d ₆ ) 8.29 (s, IH), 7.98 (s, IH), 7.98-7.76 (d, J=8Hz, IH), 7.69-7.67 (d, J=8Hz, IH), 7.58-7.56 (d, J=8Hz, IH), 7.21-7.18(dd, IH), 6.72-6.71 (m, IH), 6.33 (s, IH), 4.26-4.25 (m, IH), 4.04-4.05 (m, 2H), 3.71 (s, 3H), 3.44 (s, 3H), 3.27-3.22 (dd, IH), 3.15-3.13 (dd, IH), 2.29 (s, 3H), 1.17-1.13 (t, J=5.2Hz, 3H). MS (ESI): mass calculated for C24H25N3O4, 431.2; m/z found, 432.2[M+H] ⁺ .

Example 21:

[000148] ±Ethyl-2-(7-(4-chlorophenyl)-2-isopropyl-9-methoxy-3-oxo-3, 5-dihydro- 2H-benzo [c]pyrido [3 ,4-e] azepin-5-yl)acetate

MS (ESI): mass calculated for C27H27CIN2O4, 478.1; m/z found, 479.1[M+H] ⁺ Example 22:

[000149]+Ethyl-2-(7-(4-chlorophenyl)-9-fluoro-2-methyl-3-oxo -3,5-dihydro- benzo[c]pyrido[3,4-e]azepin- -yl)acetate

MS(ESI): mass calcd for C24H20CIFN2O3, 438.1 ; m/z found, 439.1 [M+H] ⁺ . Example 23:

[000150]+Ethyl-2-(7-(2,6-difluorophenyl)-9-methoxy-2-methyl- 3-oxo-3,5-dihydro- 2H-benzo[c]pyrido[3,4-e]azepin-5-yl)acetate

Example 24:

[000151] ±Ethyl-2-(7-(4-chloro-2-methylphenyl)-9-methoxy-2-methyl-3- oxo-3,5- dihydro-2H-benzo[c]pyrido -e]azepin-5-yl)acetate

MS(ESI): mass calcd for C26H25CIN2O4, 464.2; m/z found, 465.2 [M+H] ⁺ .

Example 25

[000152]±2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo- 3,5dihydro2Hbenzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetami de.

The compound was synthesized according to the procedure for example 8. ¹ H NMR (DMSO-de, 400MHz,): 5(ppm) 8.13 (br. s., 1H), 7.99 (s, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.48 - 7.38 (m, 4H), 7.25 - 7.24 (m, 1H), 6.73 (d, J = 2.0 Hz, 1H). 6.35 (s, 1H), 4.24 (t, J = 7.2 Hz, 1H), 3.73 (s, 3H), 3.44 (s, 3H), 3.08 - 3.04 (m, 2H), 2.93 - 2.91 (m, 2H), 1.00 (t, J = 7.6 Hz, 3H). MS (ESI): mass calcd. for C25H24CIN3O3, 449.1 ; m/z found, 450.4[M+H] ⁺

[000153] Chiral separation conditions, 25A and 25B

Analytical conditions:

Column: chiralpak IA (250mm X 4.6mm X 5im)

Mobile phase: MtBeTPA w ith 0.1%TFA (70:30)

Flow rate: l.OmL/min; Injection Volume: 20.00 ul

PDA detector, wavelength: 261.0 nm

Example 25A:

[000154] (S)-2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3,5-dihyd ro-2H- benzo[c]pyrido[3,4-e]azepin- -yl)-N-ethylacetamide.

MS (ESI): mass calcd. for C25H24CIN3O3, 449.1; m/z found, 450.2[M+H] ⁺ . Example 25B:

[000155] (R)-2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3,5-dihyd ] benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide.

MS (ESI): mass calcd. for C25H24CIN3O3, 449.1; m/z found, 450.2[M+H]

The following compounds were synthesized using the procedure for syntht

Example 26:

[000156] ±2-(7-cyclohexyl-9-methoxy-2-methyl-3-oxo-3,5-dihydro-2H- benzo[c]pyrido[3,4-e]azepi -5-yl)-N-ethylacetamide

1H NMR (DMSO-d6), 5(ppm): 8.02 (br.s., 1H) 7.90 (s, 1H) 7.48-7.46 (d J=8.4Hz, 1H) 7.16-7.15 (m, 1H) 7.12-7.10 (m, 1H), 6.28 (s, 1H), 4.01 (t, J = 6.8 Hz, 1H), 3.83 (s, 3H), 3.43 (s, 3H), 3.04-2.97 (m, 2H), 2.89-2.70 (m, 3H), 1.82-1.00 (m, 9H), 0.96 (t, J=7.2Hz, 3H), 0.67-0.59 (m, 1H). MS(ESI): mass calcd for C25H31N3O3, 421.2; m/z found, 422.5[M+H] ⁺

Compound 26 was chiral separated (26A and 26B) following the procedures used for separating 25A and 25B

Example 26A:

[000157] (S)-2-(7-cyclohexyl-9-methoxy-2-methyl-3-oxo-3,5-dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

MS(ESI): mass calcd for C25H31N3O3, 421.2; m/z found, 422.5[M+H]

Example 26B:

[000158] (R)-2-(7-cyclohexyl-9-methoxy-2-methyl-3-oxo-3,5-dihydro-2H- benzo[c]pyrido[3,4-e]azepi -5-yl)-N-ethylacetamide

MS(ESI): mass calcd for C25H31N3O3, 421.2; m/z found, 422.5[M+H]

Example 27:

[000159]±2-(9-methoxy-2-methyl-3-oxo-7-(pyridin-2-yl)-3,5-d ihydro-2H- benzo[c]pyrido[3,4-e]azepi -5-yl)-N-ethylacetamide

1H NMR (DMSO-d6): 5(ppm) 8.45 (d, J=4Hz, IH), 8.14 (br. s., IH), 7.97 (s, IH), 7.92 - 7.82 (m, 2H), 7.57 (d, J=12Hz, IH), 7.42-7.39 (m, IH), 7.20-7.18 (m, IH), 6.71 (s, IH), 6.36 (s, IH), 4.31 (t, J= 6.4Hz, IH), 3.71 (s, 3H), 3.44 (s, 3H), 3.08-3.05 (m, 2H), 2.94-2.93 (m, 2H), 1.01 (t, J= 7.2 Hz, 3H). MS (ESI): mass calculated for C24H24N4O3, 416.1; m/z found, 417.3.1[M+H] ⁺ .

Compound 27 was chiral separated (27A and 27B) following the procedures used for separating 25A and 25B

Example 27A:

[000160] (S)-2-(9-methoxy-2-methyl-3-oxo-7-(pyridin-2-yl)-3,5-dihydro -2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

MS (ESI): mass calculated for C24H24N4O3, 416.1 ; m/z found, 417.3.1 [M+H]

Example 27B:

[000161] (R)-2-(9-methoxy-2-methyl-3-oxo-7-(pyridin-2-yl)-3,5-dihydro -2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

MS (ESI): mass calculated for C24H24N4O3, 416.1 ; m/z found, 417.3.1 [M+H] ⁺ . Example 28:

[000162]±2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3,5 -dihydro-2H- benzo[c]pyrido[3,4-e]azepin- -yl)acetamide

1H NMR (DMSO-d6): 5(ppm) 12.28 (s, IH), 8.01 (s, IH), 7.63 (d, J = 8.4Hz, IH), 7.45-7.40 (m, 4H), 7.26-7.23 (m, IH), 6.74 - 6.71 (m, IH), 6.31 (s, IH), 4.17 (t, J = 3.8 Hz, IH), 3.73 (s, 3H), 3.45 (s, 3H), 3.13-3.08 (m, 3H). MS (ESI): mass calcd. for C23H20CIN3O3, 421.8; m/z found, 423.1 [M+H] ⁺ . Example 29:

[000163]±2-(7-(4-chlorophenyl)-9-hydroxy-2-methyl-3-oxo-3,5 -dihydro-2H- benzo[c]pyrido[3,4-e]azepin- -yl)-N-ethylacetamide

1H NMR (DMSO-Je, 400 MHz) δ (ppm): 9.79 (s, IH), 8.12 (br.s., IH), 7.94 (s, IH), 7.5 (d, = 8.8 Hz, IH), 7.45-7.38 (m, 4H), 7.04 - 7.01 (m, IH), 6.60-6.59 (m, IH), 6.33 (s, IH), 4.22 (t, = 7.2 Hz, IH), 3.43 (s, 3H), 3.08-3.03 (m, 2H), 2.93-2.88 (m, 2H), 1.00(t, J = 7.2 Hz, 3H). MS (ESI): mass calculated for C24H22CIN3O3, 435. m/z found, 436.1 [M+H] _.

Example 30:

[000164] ±2-(7-(cyclopropylmethyl)-9-methoxy-2-methyl-3-oxo-3,5-dihy dro-2H- benzo[c]pyrido[3,4-e]azepi -5-yl)-N-ethylacetamide

1H NMR (DMSO-de, 400MHz,): 5(ppm) 8.03 (br. s, 1H), 7.91 (s, 1H), 7.49 (d, J = 8.8 Hz, 1H), 7.20 (d, J = 2.8 Hz, 1H), 7.13 (dd, Jl = 2.4 Hz, J2 = 8.8 Hz, 1H), 6.28 (s, 1H), 4.05 (t, J = 7.2 Hz, 1H), 3.83 (s, 3H), 3.44 (s, 3H), 3.10 - 2.95 (m, 2H), 2.85 - 2.76 (m, 3H), 2.34 - 2.25 (m, 1H), 0.96 (t, J = 7.2 Hz, 3H), 0.65 - 0.55 (m, 1H), 0.24 - 0.15 (m, 2H), (-) 0.05 - (-) 0.12 (m, 2H). MS (ESI): mass calcd. for C23H27N3O3, 393.2; m/z found, 394.2 [M+H] ⁺ .

Compound 30 was chiral separated (30A and 30B) following the procedures used for separating 25A and 25B

Example 30A:

[000165] (S)-2-(7-(cyclopropylmethyl)-9-methoxy-2-methyl-3-oxo-3,5-di hydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

MS (ESI): mass calcd. for C23H27N3O3, 393.2; m/z found, 394.2 [M+H] ⁺ .

Example 30B:

[000166] (R)-2-(7-(cyclopropylmethyl)-9-methoxy-2-methyl-3-oxo-3,5-di hydro-2H- benzo[c]pyrido[3,4-e]azepi -5-yl)-N-ethylacetamide

MS (ESI): mass calcd. for C23H27N3O3, 393.2; m/z found, 394.2 [M+H] ⁺ . Example 31:

[000167]±2-(7-(4-chlorophenyl)-9-(difluoromethoxy)-2-methyl -3-oxo-3,5-dihydro- 2H-benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

MS (ESI): mass calculated for C25H22CIF2N3O3, 485.1 ; m/z found, 486.1 [M+H]

Example 32:

[000168]±2-(9-methoxy-2-methyl-3-oxo-7-(trifluoromethyl)-3, 5-dihyd]

benzo[c]pyrido[3,4-e]azepi -5-yl)-N-ethylacetamide

1H-NMR (DMSO-Je, 400 MHz) δ (ppm): 8.10 (t, / = 5.2 Hz, 1H), 8.04 (s, 1H), 7.68 (d, = 8.8 Hz, 1H), 7.38-7.32 (m, 1H), 7.11 (s, 1H), 6.39 (s, 1H), 4.35-4.30 (m, 1H), 3.85 (s, 3H), 3.44 (s, 3H), 3.08-2.90 (m, 4H), 0.97 (t, = 6.8 Hz, 3H). MS (ESI): mass calculated for C20H20F3N3O3, 407.1 ; m/z found, 408.3 [M+H] ⁺

Compound 32 was chiral separated (32A and 32B) following the procedures used for separating 25A and 25B

Example 32A:

[000169] (S)-2-(9-methoxy-2-methyl-3-oxo-7-(trifluoromethyl)-3,5-dihy d] benzo[c]pyrido[3,4-e]azepi -5-yl)-N-ethylacetamide

MS (ESI): mass calculated for C20H20F3N3O3, 407.1 ; m/z found, 408.3[M+H] ⁺ , Example 32B:

[000170] (R)-2-(9-methoxy-2-methyl-3-oxo-7-(trifluoromethyl)-3,5-dihy dro-2H- benzo[c]pyrido[3,4-e]azepi -5-yl)-N-ethylacetamide

MS (ESI): mass calculated for C20H20F3N3O3, 407.1; m/z found, 408.3[M+H]

Example 33:

[000171]±2-(7-(4-cyanophenyl)-9-methoxy-2-methyl-3-oxo-3,5- dihydro-2H- benzo[c]pyrido[3,4-e]azepi -5-yl)-N-ethylacetamide

1H NMR (DMSO-d6), 5(ppm): 8.15 (t, J = 7.4Hz, 1H), 8.00(s, 1H), 7.84 (d, J = 8.4Hz, 1H), 7.64 (d, J = 8.8Hz, 1H), 7.56 (d, J =8.4Hz, 2H), 7.41-7.45 (m, 1H), 7.25- 7.28 (m, 1H), 6.71 (d, J = 2.8Hz, 1H), 6.36 (s, 1H), 4.28 (t, J = 7.2Hz, 1H), 3.73 (s, 3H), 3.44 (s, 3H), 3.03-3.08 (m, 2H), 2.92-2.95 (m, 2H), 1.01 (t, J = 8.0Hz, 3H); MS(ESI): mass calcd for C26H24N4O3, 440.1; m/z found, 441.2[M+H] ⁺ Example 34:

[000172]±2-(9-methoxy-2-methyl-7-(5-methylpyridin-2-yl)-3-o xo-3,5-dihydro-2H- benzo[c]pyrido[3,4-e]azepi -5-yl)-N-ethylacetamide

1HNMR: (400 MHz, DMSO-d ₆ ), 5(ppm): 8.29 (s, IH), 8.13 (br.s., IH), 7.96 (s, IH), 7.81 (d, J=8Hz, IH), 7.68 (d, J=5.2Hz, IH), 7.55 (d, J=8Hz, IH), 7.19-7.17 (m, IH), 6.39 (s, IH), 4.28 (t, J= 6.4Hz, IH), 3.71 (s, 3H), 3.44 (s, 3H), 3.08-3.04 (m, 2H), 2.93-2.91 (m, 2H), 2.29 (s, 3H), 1.03 (t, J=8Hz, 3H). MS(ESI): mass calcd for C25H26N4O3, 430.1; m/z found, 431.2[M+H] ⁺

Example 35:

[000173]±2-(7-(4-chlorophenyl)-2-methyl-3-oxo-9-(trifluo romethyl)-3,5-dihyd] benzo[c]pyrido[3,4-e]azepi -5-yl)-N-ethylacetamide

1H NMR (DMSO-d ₆ ,400MHz,): 5(ppm) 8.20 (s,lH), 8.13 (br.s., 1H), 8.01 (d, J = 8.0Hz, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.53 (s, 1H), 7.46 (d, J = 8.0Hz, 2H), 7.37 (d, J = 8.0Hz, 2H), 6.39 (s,lH), 4.23 (t,J= 8.0Hz, 1H), 3.47 (s, 3H), 3.09 - 3.03 (m, 2H), 2.95 (d, J=8.0Hz, 2H), 1.00 (t , J=8.0 Hz, 3H). MS(ESI): mass calcd for C25H21CIF3N3O2, 487.1; m/z found, 488.3[M+H] ⁺ LCMS: 488.3 [M+H].

Example 36:

[000174] ±2-(7-(4-chlorophenyl)-2-isopropyl-9-methoxy-3-oxo-3,5-dihy dro-2H- benzo[c]pyrido[3,4-e]azepi -5-yl)-N-ethylacetamide

1H NMR (DMSO-d ₆ ,400MHz,): 8.13 (br. s., 1H) , 7.89 (s, 1H), 7.66 (d, = 8.4 Hz, 1H), 7.50 - 7.40 (m , 4H), 7.27 - 7.23 (m, 1H), 6.75(d, J = 2.4 Hz, 1H), 6.35 (s, 1H), 5.10 - 4.95 (m, 1H), 4.25 (t, J = 7.2 Hz, 1H), 3.74 (s, 3H), 3.10 - 3.05 (m, 2H), 2.92 (d, J = 6.8 Hz, 2H), 1.38 (d, J = 6.4 Hz, 3H), 1.26 (d, J = 7.2 Hz, 3H), 1.01 (t, J = 7.6Hz, 3H); MS(ESI): mass calcd for C27H28CIN3O3, 477.1; m/z found, 478.1[M+H] ⁺ Example 37:

[000175] ±2-(7-(4-chlorophenyl)-9-fluoro-2-methyl-3-oxo-3,5-dihydro- 2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

1H NMR (DMSO-d ₆ ,400MHz,): 5(ppm) 8.13 (t, J=8Hz, IH), 8.06( s,lH), 7.77-7.73 (m, IH), 7.56-7.51 (m, IH), 7.46-7.36 (m, 4H), 7.11-7.086 (dd, J=4Hz, J=4Hz, IH), 6.36 (s,lH), 4.22(t ,J= 8.0Hz, IH), 3.45(s, 3H), 3.09 - 3.03 (m, 2H), 2.94-2.92 (m, 2H), 1.00 (t , =8.0 Hz 3H). MS(ESI): mass calcd for C24H21CIFN3O2, 437.1; m/z found, 438.1[M+H] ⁺ .

Example 38:

[000176] ±2-(7-(2,6-difluorophenyl)-9-methoxy-2-methyl-3-oxo-3,5-dih ydro-2H- benzo[c]pyrido[3,4-e]azepi -5-yl)-N-ethylacetamide

1H NMR (DMSO-d ₆ ,400MHz,): 5(ppm) 8.06-8.05 (m, 2H), 7.64 (d, J = 8.4 Hz, IH), 7.56 -7.45 (m, IH), 7.23-7.20 (m, IH), 7.10 - 7.08 (m, 2H), 6.59 (s,lH), 6.36 (s, IH), 4.33 (t, = 6.8 Hz, IH), 3.73 (s, 3H), 3.48(s, 3H), 3.05 - 3.03 (m, 2H), 2.89 (d, J = Hz, 2H), 1.00 (t, = 7.2Hz, 3H). MS (ESI): mass calculated for C25H23F2N3O3, 451.2; m/z found, 452.2[M+H] ⁺ . Example 39:

[000177] ±2-(7-(4-chloro,2-methylphenyl)-9-methoxy-2-methyl-3-oxo-3, 5-dihydro- 2H-benzo[c]pyrido[3,4-e]azepin-5-yl)-N-ethylacetamide

1H NMR (DMSO-d ₆ ,400MHz,), 5(ppm): 8.09 (br. s., 1H) , 8.03(s, 1H), 7.62 (d, = 8.8 Hz, 1H), 7.27 (s, 1H), 7.25 - 7.20 (m, 2H), 6.98 (d, J = 6.4 Hz, 1H), 6.44 (d, J = 2.4 Hz, 1H), 6.31 (s, 1H), 4.28 (t, J = 8.4 Hz, 1H), 3.67 (s, 3H), 3.48 (s, 3H), 3.10 - 2.78 (m, 4H), 1.94 (s, 3H), 1.00 (t, J = 7.2Hz, 3H); MS(ESI): mass calcd for C26H26CIN3O3, 463.1; m/z found, 464.1 [M+H] ⁺ . Example 40:

[000178]±2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo- 3,5-dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-(4-hydroxyphenyl)acetami de

1H NMR (DMSO-de) :- 5(ppm) 9.96 (s, 1H), 9.11 (br.s., 1H), 8.02(s, 1H), 7.64 (d, J 8.4Hz, 1H), 7.45-7.40 (m, 4H), 7.33 (d, J = 7.6Hz, 2H), 7.26-7.24 (m, 1H), 6.73 (d, J 2.8 Hz, 1H), 6.66(d, J = 8.4Hz, 2H), 6.41 (s, 1H), 4.3 l(t, J = 6.8 Hz, 1H), 3.73 (s, 3H), 3.45 (s, 3H), 3.12-3.08 (m, 2H); MS (ESI): mass calcd for C29H24CIN3O4, 513.1 ; m/z found, 514.4 [M+H] ^~ .

Compound 40 was chiral separated (40A and 40B) following the procedures used separating 25A and 25B

Example 40A:

[000179] (S)-2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3,5-dihyd ro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)-N-(4-hydroxyphenyl)acetami de

MS (ESI): mass calcd for C29H24CIN3O4, 513.1; m/z found, 514.4 [M+H] ⁺ . Example 40B:

[000180] (R)-2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3,5-dihyd ] benzo[c]pyrido[3,4-e]azepin-5-yl)-N-(4-hydroxyphenyl)acetami de

MS (ESI): mass calcd for C29H24CIN3O4, 513.1; m/z found, 514.4 [M+H] ⁺ .

Example 41:

[000181]±7-(4-chlorophenyl)-9-methoxy-2,5-dimethyl-2H-benzo [c]pyrido[3,4- e]azepin-3(5H)-one

Step a: N-(l -(5-bromo- 1 -methyl-2-oxo- 1,2-dihydrop yridin-4-yl)ethyl)-2- methylpropane-2-sulfinamide [000182] To a stirred solution of (E)-N-((5-bromo-l-mefhyl-2-oxo-l,2- dihydropyridin-4-yl)methylene)- 2-methylpropane-2-sulfinamide (X, 0.3g, 0.94 mmol) in dry THF was cooled to -78 °C and then methylmagnesium bromide (0.13 mL, 1.12 mmol) was added drop wise and stirred at same temperature for 2h and then stirred at room temperature for another lh. Reaction mixture was quenched with ammonium chloride solution and extracted with ethylacetate (25 mL x 2). The organic layer was dried, concentrated under vacuum and purified by column chromatography using methanol/DCM as eluent to get N-(l-(5-bromo-l-mefhyl-2- oxo-l,2-dihydropyridin-4-yl)ethyl)-2-methylpropane-2-sulfina mide (0.27g, 86%) as yellow solid. MS (ESI): mass calcd for Ci ₂ Hi ₉ BrN ₂ 0 ₂ S, 334.0; m/z found, 335.0 [M+H] ⁺ .

Step b: N-( 1 -(5-(2-(4-chlorobenzoyl)-4-methoxyphenyl)- 1 -methyl-2-oxo- 1 ,2- dihydropyridin-4-yl)ethyl)-2-methylpropane-2-sulfinamide

[000183]To a stirred solution of N-(l-(5-bromo-l-methyl-2-oxo-l,2-dihydropyridin- 4-yl)ethyl)-2-methylpropane-2-sulfinamide (XI, 0.33g, 0.98 mmol) and (4- chlorophenyl)(5-methoxy-2-(4,4,5,5-tetramethyl-l,3,2-dioxabo rolan-2- yl)phenyl)methanone (VII, 0.44 lg, 1.18 mmol) in toluene (20 mL) To this mixture, was added sodium bicarbonate (249 mg, 2.96 mmol) and Pd(PPh ₃ ) ₄ (0.114g, 0.098 mmol) nitrogen was purged for lOmin at room temperature in inert condition. The reaction mixture was heated to 110° C and stirred for 16h. To the reaction mixture water was added and extracted with ethyl acetate, the organic layer was dried over by sodium sulfate and concentrated. The crude product was purified by column chromatography the product eluted at 6% of MeOH/DCM. to get the product (280 mg, 57 % yield), MS (ESI): mass calcd. for C ₂₆ H ₂₉ C1N ₂ 0 ₄ S, 500.2; m/z found, 501.1 [M+H]+.

StepC: 7-(4-chlorophenyl)-9-methoxy-2,5-dimethyl-2H-benzo[c]pyrido[ 3,4-e]azepin- 3(5H)-one To a stirred solution of N-(l-(5-(2-(4-chlorobenzoyl)-4-methoxyphenyl)-l-methyl-2- oxo-l,2-dihydropyridin-4-yl)ethyl)-2-methylpropane-2-sulfina mide (XII, 0.280g, 0.56 mmol) in 4N HCl in dioxane (5 mL) was stirred at room temperature for lh. After completion of reaction the solvent was evaporated then crude residue was basified with sodium bicarbonate and organic layer was extracted with DCM then dried over by sodium sulfate and concentrated and the crude was purified by column chromatography by using 5% methanol/DCM as eluent to get the compound 41 as pale yellow solid . (140 mg, 66 % yield).

1H NMR (DMSO-d ₆ ,400MHz,): 5(ppm) 7.98 (s, 1H), 7.60 (d, J = 9.2 Hz, 1H), 7.46 - 7.41 (m, 4H), 7.25 - 7.20 (m, 1H), 6.74 (d, J = 2.4 Hz, 1H), 6.35 (s, 1H), 3.94 (q, J = 6.1 Hz, 1H), 3.73 (s, 3H), 3.45 (s, 3H), 1.62 (d, J = 6.4Hz, 3H). MS (ESI): mass calculated for C22H19CIN2O2, 378.1 ; m/z found, 379.1[M+H] ⁺ .

Compound 41 was chiral separated (41A and 41B) following the procedures used for separating 25a and 25b

Example 41A:

[000184] (S)-7-(4-chlorophenyl)-9-methoxy-2,5-dimethyl-2H-benzo[c]pyr ido[3,4- e]azepin-3(5H)-one

MS (ESI): mass calculated for C ₂ 2H ₁₉ C1N ₂ 02, 378.1; m/z found, 379.1[M+H] Example 41B: [000185] (R)-7-(4-chlorophenyl)-9-methoxy-2,5-dimethyl-2H-benzo[c]pyr ido[3,4- e]azepin-3(5H)-one

MS (ESI): mass calculated for C22H19CIN2O2, 378.1; m/z found, 379.1[M+H] ⁺ . Example 42:

[000186] ±7-(4-chlorophenyl)-9-methoxy-2-methyl-2H-benzo[c]pyrido[3, 4-e]azepin- 3(5H)-one

The compound was synthezied using the procedure in the example 41

1H NMR (DMSO- d ₆ , 400MHz,): 5(ppm) 8.03 (s, 1H), 7.60 (d, J = 8.8Hz, 1H), 7.47 - 7.41 (m, 4H), 7.23 (dd, J = 2.4 Hz, 8.8 Hz, 1H), 6.71 (d, J = 2.8 Hz, 1H), 6.46 (s, 1H), 4.70 (d, J = 10.0 Hz, 1H), 3.86 (d, J = 10 Hz, 1H), 3.72 (s, 3H), 3.45 (s, 3H). MS (ESI): mass calcd. for C ₂ iH ₁₇ ClN ₂ 0 ₂ , 364.1; m/z found, 365.1 [M+H]+. Example 43: '

[000187] ±2-(7-(4-chlorophenyl)-2-methyl-3-oxo-9-(trifluoromethyl)-3 ,5-dihyd] benzo[c]pyrido[3,4-e]azepin-5-yl)acetic acid

[000188] Ammonium formate (0.41 g, 0.650 mmol) was added to a stirred solution of 3-(5-(2-(4-chlorobenzoyl)-4-(trifluoromethyl)phenyl)-l-methy l-2-oxo-l,2- dihydropyridin-4-yl)acrylic acid (0.150 g, 0.325 mmol) dissolved in efhanol (5 mL), was carried out in seal tube at 90°C. After 15h the reaction mixture was cooled to room temperature and concentrated to get mass, which was taken in ethyl acetate and water. The organic layer was separated and dried over sodium sulfate and concentrated to get residue. The crude was purified by comb flash eluting with 0-80% ethyl acetate/hexane. The pure fractions were concentrated to obtain 2-(7-(4- chlorophenyl)-2-methyl-3-oxo-9-(trifluoromethyl)-3,5-dihydro -2H- benzo[c]pyrido[3,4-e]azepin-5-yl)acetic acid ( 0.08g, 57% yield) as a off-white solid. . 1H NMR (DMSO-d ₆ ,400MHz,): 5(ppm) 12.32 (s , 1H ) , 8.01 (s , 1H) , 8.02-8.00 ( m, 1H) , 7.96-7.94 (d, =8Hz, 1H) , 7.54(s , 1H) , 7.50-7.48 (d, = 8Hz, 2H) , 7.39- 7.37( d , /=8Hz, 2H ), 6.36 (s, 1H), 4.176 (t, = 8Hz, 1H), 3.47 (s, 3H), 3.17-3.12 ( 2H); MS(ESI): mass calcd for C23H16CIF3N2O3, 460.1; m/z found, 461.1[M+H] ⁺ .

Example 44:

[000189]±2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo- 3,5-dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)acetic acid

o a stirred solution of ethyl 2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3,5- dihydro-2H-benzo[c]pyrido[3,4-e]azepin-5-yl)acetate (2.1g, 4.65 mmol) in THF (30ml) was added IN NaOH (9.3 ml, 9.31 mmol) and stirred at rt for 3 hours. Reaction mixture was neutralized with IN HCl solution (9.3 ml) and extracted with 5% MeOH/DCM (50 ml x 2). The organic layer was dried over sodium sulphate and concentrated under vacuum to get compound 44 (1.95g, 98.9%) as off-white solid. MS(ESI): mass calcd for C23H19CIN2O4, 422.1; m/z found, 423.1 [M+H] ⁺ .

Example 45:

[000190] ±tert-butyl ((7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3,5-dihydro- 2H-benzo[c]pyrido[3,4-e]azepin-5-yl)methyl)carbamate

44 45

To a stirred solution of 2-(7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo-3,5-dihydro- 2H-benzo[c]pyrido[3,4-e]azepin-5-yl)acetic acid (example 44, 0.4 g, 0.945 mmol) in t- BuOH (20 mL), TEA(0.198 mL, 1.41 mmol), diphenylphosphoryl azide (0.225 mL, 1.04 mmol) at room temperature. The mixture was stirred at 105 °C for 24 h. The mixture was cooled to room temperature and concentrated under vacuum. The crude was dissolved in ethyl acetate and washed with saturated NaHC0 ₃ solution and brine, dried over sodium sulphate , concentrated under reduced pressure. The crude was purified by combiflash purifier by using 5-100% ethyl acetate/ hexane as the eluent to get the product as off white solid. (0.15 g, 32 % yield). 1H NMR (DMSO- d ₆ ,400MHz,): 5(ppm) 7.99 (s, lH), 7.61 (d, J = 8.4 Hz, 1H), 7.50 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.8 Hz, 2H),7.24-7.22 (m, 1H), 7.01 - 6.92 (m, 1H), 6.75 (d, J = 2.8 Hz, 1H), 6.42 (s,lH), 3.90 - 3.86 (m, 2H), 3.73 (s, 3H),3.70 - 3.63 (m,lH), 3.44 (s, 3H), 1.32 (s,9H). MS (ESI): mass calcd. for C ₂ 7H ₂₈ C1N ₃ 04, 493.2; m/z found, 494.1[M+H] ⁺ .

Example 46:

[000191]±N-((7-(4-chlorophenyl)-9-methoxy-2-methyl-3-oxo -3,5-dihydro-2H- benzo[c]pyrido[3,4-e]azepin-5-yl)methyl)acetamide

Step A: 5-(aminomethyl)-7-(4-chlorophenyl)-9-methoxy-2-methyl-2H- benzo[c]pyrido[3,4-e]azepin-3(5H)-one hydrochloride

[000192] To a stirred solution of tert-butyl ((7-(4-chlorophenyl)-9-methoxy-2-methyl- 3-oxo-3,5-dihydro-2H-benzo[c]pyrido[3,4-e]azepin-5-yl)methyl )carbamate (example 45, 0.15 g, 0.3 mmol) in dioxan (1 mL), dioxin.HCl (5 mL) at 0°C under nitrogen atmosphere. The mixture was concentrated under vacuum. The crude was washed with diethyl ether twice and dried under vacuum (O.lg crude). MS (ESI): mass calcd. for C22H21CI2N3O2, 393.1 ; m/z found, 394.1[M+H] ⁺ .

Step B: To a stirred solution of 5-(aminomethyl)-7-(4-chlorophenyl)-9-methoxy-2- methyl-2H-benzo[c]pyrido[3,4-e]azepin-3(5H)-one hydrochloride (XIII, O.lg crude, 0.25 mmol) in DCM (5 mL), triethyl amine (0.052 mL, 0.375 mmol) at 0°C under nitrogen atmosphere. The mixture was stirred for 15 mins. Then acetyl chloride (0.021 mL, 0.3 mmol) was added at 0°C. The mixture was stirred for 1 h at room temperature. The mixture was quenched with water and extracted with DCM, dried over sodium sulphate, and dried under vacuum (0.006g). 1H NMR (DMSO-d ₆ ,400MHz,): 5(ppm) 8.06 (br.s.,lH), 7.99 (s,lH), 7.61 (d, J = 8.4 Hz, 1H), 7.50 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.8 Hz, 2H), 7.24-7.22 (m, 1H), 6.73 (d, J = 2.8 Hz, 1H), 6.4 (s, lH), 3.9-3.85 (m, 2H), 3.72 (s, 3H), 3.71 - 3.69 (m,lH),3.48 (s, 3H), 1.7 (s,3H).MS (ESI): mass calcd. for C24H22CIN3O3, 435.13; m/z found, 436.2[M+H] ⁺ .

BIOLOGICAL METHODS BRD4 AlphaLISA (Perkin Elmer)

[000193] Compounds were diluted by step-down dilution method (final concentration of DMSO was 1%) and added to the wells of a 384 well opti plate at desired concentrations. 5 nM BDR4-BD1 enzyme (produced in-house) and 12 nM of biotinylated substrate were added to the wells, covered and incubated at room temperature (RT) for 1 h. At the end of 1 h 250 ng of GSH acceptor beads were added to the well and incubated for 1 h at RT; then 500 ng of streptavidin donor beads were added and incubated again for 1 h at RT. Plates were read in a Pherastar reader at 680 nm excitation and 570 nm emission. As detailed above, compounds were tested for both BRD4 enzyme inhibitory activities and IC ₅₀ were determined. The activities of selected compounds are listed in Table 1

Anticancer activity: Alamar Blue Assay

[000194] The impact of the compounds on cancer cell proliferation was determined using the AML cell line MV4-11 (ATCC) in a 3-day proliferation assay. MV4-11 cells were maintained in RPMI supplemented with 10% FBS at 37°C, 5% C0 ₂ . For compound testing, MV4-11 cells were plated in a 96- well black bottom plate at a density of 15,000 cells/well in ΙΟΟμΙ. culture media and incubated at 37°C overnight. Compound dilution series were prepared in DMSO via a 3-fold serial dilution from ΙΟΟμΜ to 0.005μΜ. The DMSO dilution series were then diluted with media, with the final compound concentrations added to the wells ranging from 10μΜ to 0.0005μΜ. After the additions of compounds, the cells were incubated for 72h and the numbers of viable cells were determined using the Alamar Blue assay (Invitrogen), according the manufacturers suggested protocol. The fluorescent readings from the Alamar Blue assay were normalized to the DMSO treated cells and analyzed using the GraphPad Prism software with sigmoidal curve fitting to obtain EC ₅₀ . The selected compounds activities are listed in Table 1.

[0001 5] Table 1: Selected list of compounds with BRD4-BD1 IC ₅₀ and Anticancer activity

Determination of biomarker C-Myc and p21 in MV4-11 cells.

[000196] MV4- 11 cells were seeded in a 24-well plate at a density of 0.2xl0 ⁶ cells/ml and incubated at 37°C overnight. The cells were treated with the compounds at the indicated concentrations and time points. The cells were harvested at the indicated time points and protein extraction was performed using the RIPA buffer. For the tumor samples, the protein was extracted by homogenizing a small piece of the tumor in RIPA buffer. 25-5(^g protein was resolved in SDS-PAGE and subjected to Western Blotting. The antibodies against cMYC and p21 were purchased from Cell Signaling. The antibody against β-Actin was purchased from Sigma.

In vivo Xenograft model

[000197] The effects of the compounds to inhibit the growth of MV4-11 xenograft tumors were evaluated. Briefly, 5xl0 ⁶ cells of MV4-11 cells; diluted 1: 1 with matrigel were injected subcutaneously on the upper flanks of female nude mice (Charles Rivers Labs). The total volume injected per animal was 200μΙ _^ . The mice were observed for approximately 15-20 days with concomitant tumor volume measurement. The treatment was initiated post-randomization when the average tumor volume was approximately 100mm . The compounds were formulated in 0.02% Tween-80, 0.5% Methylcellulose and administered by oral gavage. The tumors were measured by a pair of callipers thrice a week starting at the time of size match, and tumor volumes were calculated according to the formula V=(LxWxH)x0.52 (V:volume, mm ; L:length, mm; W:width, mm; H:height, mm). The tumor volume and body weight were measured for the duration of the experiment, until the mean tumor volume in each group reached an endpoint of > 1000mm . Compounds of formula I showing greater 50% tumor growth inhibition are considered as active.

[000198] Although the subject matter has been described in considerable detail with reference to certain embodiments thereof, other embodiments are possible. As such, the spirit and scope of the invention should not be limited to the description of the embodiments contained herein.